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ABSTRACT 
 
 
The objective of this study is to synthesize and characterize antimicrobial, bio-polymer 
based silver nanomaterials composite coatings, for use in chronic indwelling medical devices, 
and bioscaffolds. The coatings and bioscaffolds are comprised of novel biomass mediated silver 
nano particles (SNP) that are biocompatible, highly concentrated, highly pure, cost-effective, 
polydispersed and compatible with a range of polymer systems applicable for use with existing 
chronic indwelling medical devices.  
This thesis is divided into three main chapters. In Chapter 1, detailed review on the need 
for antimicrobial nanocomposite coatings for chronic indwelling medical devices along with 
different SNP synthesis and characterization methods is provided. In Chapter 2 a comprehensive 
description of biocompatible/bioresorbable poly (L-lactide) (PLLA) based thin film coatings 
comprised of novel 25-75 nm silver nano particles SNP is provided. The particle and film 
morphology is characterized using Transmission Electron Microscopy (TEM), Atomic Force 
Microscopy (AFM) and UV-Visible Spectroscopy. The release rate of SNP is profiled by 
Thermogravimetric Analysis (TGA) and Inductively Coupled Plasma Optical Emission 
Spectrometer (ICP-OES). These coatings, suitable for chronic indwelling devices, drastically 
reduce the microbial biofilm formed by Staphylococcus aureus and Escherichia coli by 3-5 log 
reduction. This chapter details the synthesis of PLLA cast-coatings and the procedure to embed 
SNP, an antimicrobial agent, at a range of concentrations to identify an optimal SNP 
concentration of 700-800 ppm that efficacious and non-cytotoxic to human epithelial carcinoma 
cells (HeLa). Chapter 3 explains the procedure of making biocompatible/bioresorbable PLLA-
PEG co-polymer block bioscaffolds designed to degrade and resorb at a controlled rate while 
providing a suitable substrate for tissue regrowth. The antimicrobial properties of these porous 
 xiii 
bioscaffolds are tested across varying concentrations of biomass mediated SNP, to determine an 
efficacious antimicrobial concentration. The bioscaffolds are efficacious as it reduces the 
Staphylococcus aureus and Escherichia coli biofilm by 92.5- 99.9%, respectively, at an 
antimicrobial SNP concentration of 800ppm. 
 
 
 
 
 1 
CHAPTER 1.  INTRODUCTION 
 
New Medicare/Medicaid regulations being phased in starting in 2008 have drastically 
reduce the reimbursement to healthcare providers for services provided related to treating 
healthcare associated conditions. Of specific concern to indwelling device manufactures are 
regulations that curtail compensation for septicemias, urinary tract infections associated with 
Foley catheter therapy and certain surgical site infections. According to the Pennsylvania Health 
Cost Containment Health Council (PHC4), in 2006,  the average additional cost to treat a patient 
who acquired a surgical site infection was $191,872 of which only ~27% of the established 
charges were reimbursed [1]. Many indwelling medical devices now incorporate traditional 
antibiotics and/or inorganic antimicrobial compounds to reduce the risk of infection associated 
with implantation. Several of these agents, which are associated with Healthcare Acquired 
Infections (HAI), have become increasingly resistant to traditional antibiotics. Bacterial stains 
such as Methicillin Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant 
Enterococcus (VRE) have demonstrated broad resistance to beta-lactam and glycopeptides based 
antibiotics and have been frequently associated with indwelling devices resulting in difficult to 
treat infections[2].  A variety of active and passive strategies have been employed to impart 
antimicrobial properties to the materials used in the construction of indwelling devices including; 
antibiotics [3], inorganic salts [4-5], inorganic nanomaterials [6-7] and organic compounds [8-
9].While these strategies have produced satisfactory results for acute indwelling devices such as; 
professional wound dressings [10], central venous catheters[11] and endotracheal tubes[12-14]; 
none of these approaches to incorporating an antimicrobial has yielded an optimized solution for 
chronic indwelling device environments.  Among the device based antimicrobial solutions that 
are currently commercially available silver, in a number of forms, has a successful history of safe 
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and efficacious use against a broad spectrum of gram-positive and gram-negative microbial 
agents [15-17]. Recent advances in materials development have created novel nanoscale forms of 
silver metal that present potential advantages in efficacy, ease of integration and safety when 
compared to ionic silver or bulk metal delivery vehicles [6-7, 18-20].   
This study evaluates the applicability of a silver nanomaterial based antimicrobial 
compound as a chemo-prophylactic agent in bioresorbable/biocompatible thin film coatings and 
biological scaffolds. It determines the concentrations and contact times required for in vitro 
elimination of known titers of two model organisms, Staphylococcus aureus and Escherichia 
coli. Silver release rate and nanoparticle erosion as a function of particle concentration and thin 
film composition is characterized, along with bioresorbable films/scaffolds response to exposure 
to simulated physiological solution. The values obtained provides a baseline for follow-on in-
vitro and in vivo challenge trials, cytotoxicity studies and is used to assess how silver 
nanoparticles can best be implemented in both antimicrobial coatings for chronic indwelling 
devices and tissue scaffolds. 
1.1 Existing Antimicrobial Compounds 
1.1.1 Silver as an Antimicrobial Agent 
Silver is an oligodynamic antimicrobial compound, meaning that exposure to relatively 
low concentrations of the metal can result in substantial reduction of viable microbial organisms. 
The ionic form of the compound, Ag
+
, has been identified as the primary active agent [21], 
although some recent research indicates that the nanoscale metal form of the compound may 
have some unique antimicrobial attributes [22]. Various silver compounds have been used as 
antimicrobial agents in many healthcare related applications including; pathogen control, 
prophylaxis and therapeutic treatments. Salts [23-26], zeolites [27-29] and thin film metal 
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coatings [30] have demonstrated some utility as silver ion sources for medical devices, but 
concerns regarding cost, performance and safety have limited the broader adoption of these 
delivery vehicles in indwelling device applications.  
1.1.2 Silver Bearing Salts 
Silver bearing salts, specifically, silver nitrate, silver halides and silver sulfadiazine 
(SSD) have been used as an antimicrobial agent in applications ranging from burn treatment to 
catheter systems. The exact mechanism of silver and its salts on the microbes is still not known 
but the possible mechanism of metallic silver, silver ions and silver nanoparticles have been 
suggested after looking at the morphological and structural changes in the bacterial cells [31]. 
The silver interacts with thiol group compounds found in the respiratory enzymes of bacterial 
cells and binds to the bacterial cell wall and cell membrane, inhibiting the respiration 
process[32]. In the case of E. coli, it acts by inhibiting the uptake of phosphate and releasing 
phosphate, mannitol, succinate, proline and glutamine from E. coli cells [33-37]. The replication 
of DNA is effectively conducted when the DNA molecules are in relaxed state and loses its 
replication ability when in condensed form. When the silver ions penetrate inside the bacterial 
cells, DNA molecule condenses reducing the rate bacterial replication.  It has also been reported 
that heavy metals react with proteins by interacting with the thiol group deactivating 
proteins[31].  
Silver nitrate is a highly water soluble compound that has been used historically in the 
treatment of burns and as a prophylactic to reduce the transmission of gonorrhea to new born 
infants during birth[38]. Silver nitrate has not been used extensively as a device delivered 
antimicrobial, as its high water solubility and low chemical and thermal stability result in 
relatively short duration of release and challenges in device design and incorporation. 
 4 
Additionally, studies comparing wounds treated with silver based antimicrobials have 
demonstrated that silver nitrate, compared to other silver forms, significantly retards the re-
epithialization and neovascularzation of wound beds [24, 39]. Two halide forms of silver; silver 
chloride and silver bromide, have been explored as sources of Ag ion for medical device coatings 
but poor solubility and poor thermal stability, compared to other ionic forms, have limited their 
broader use in medical device applications [24, 40-41].  
In the 1970’s silver sulfadiazine (SSD), a salt derivative of a sulfa drug compound, was 
characterized and formulated for use in topical creams and ointments to provide a more 
efficacious and stable ionic silver delivery option for the treatment of burns and other chronic 
wounds[42]. More recently, the use of SSD as an active agent has been expanded beyond topical 
applications including incorporation in devices such as central line catheters and professional 
wound care dressings and packings [26, 43]. The mechanism of action of SSD is distinct from 
silver nitrate and silver halide compounds as it acts by disrupting the organism’s cell wall and 
releasing ionic silver through interaction with physiological solutions[42]. The compound’s poor 
solubility in aqueous environments and chemical instability has prevented its broader use in 
device based delivery systems. While SSD is less cytotoxic than silver nitrate, it is still 
significantly more toxic than many other commonly used antiseptics and antibiotic compounds, 
it can prolong wound healing and has been implicated in cases of renal failure [44-46].  
1.1.3  Silver Zeolites and Glasses 
Silver bearing zeolites and glasses, which entrap Ag ion in ceramic crystal or amorphous 
glass carriers, are the second most common source of Ag ion used in the manufacture of medical 
devices. Both the zeolites and glass compounds are relatively large, ~2-200 m hydrophilic 
particles, but each compound has distinctly different mechanisms for silver ion release. Silver 
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zeolites are typically composed of mesoporous aluminosilicate or zirconium phosphate which 
entrap Ag ion within the nanoscale pores in the crystal structure. Zeolites release Ag
+
 into 
solution through a kinetically favorable ion exchange process with Na
+
 or K
+
, ions which are 
ubiquitous in physiological environments. Exposure of high salinity physiological solutions 
typically results in an initial bolus of Ag ion release and rapid exhaustion of the bioavailable 
silver ion within the device. The micron scale ceramic carrier is largely inert and not 
biodegradable, end of life cycle analysis indicates that substantial amounts of silver in zeolites 
are not bioavailable and remain sequestered within the crystal structure. [29] 
Unlike zeolites, silver glass particles are amorphous and are typically composed of 
unstable, silver doped silica and phosphate compounds [47-48]. Silver doped glass or “bioglass”, 
as it is often referred, releases silver ion through a surface mediated corrosion process. The 
relatively large size of the particles and the chemical stability of the silver oxide form in glass 
tend to reduce the bioavailability of silver ion. Thus requiring high concentrations of bioglass, in 
the parts-per-thousand range, to achieve reasonable microbial kill rates[48]. The large size and 
slow corrosion rate of the bioglasses limit their use in bioresorbable thin film coatings. Zeolites 
and bioglasses share some common features; the silver in both classes of compounds tend to 
photo-reduce on exposure to light, reducing the amount of bioavailable silver[49]. Also, the 
hydrophilic nature of the particle surface reduces the solubility of both types of materials in 
hydrophobic polymer and solvent systems.  
1.1.4 Other Silver Sources 
Bulk metal silver coatings have been used to impart antimicrobial properties to several 
types of medical devices including; catheters, endotracheal tubes and heart valves.  The silver 
coated heart valve device produced by St. Jude Medical, is notable in that the device’s bulk silver 
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coating promoted the onset of endocarditis in tissue immediately in contact with the valve 
material leading to device rejection[50-51].  This unexpected cytotoxicity associated with long 
term exposure to bulk silver coated implants has limited its use to device designed for acute 
applications.  
The recent commercial availability of metallic, nanoparticle silver polymer additives has 
created a renewed interest in silver based antimicrobials [6, 43, 52]. Advances in synthetic 
techniques used for particle production have greatly reduced cost, improved yields, and 
diversified the available particle chemistries and morphologies [53-58]. Shapes such as rods, 
spheres, pyramids and other polygons can be combined with a myriad of chemical functionalities 
to create a wide window of particle solubility and reactivity. This highly flexible nanoscale form 
of metallic silver potentially addresses many of the limitations of ionic silver delivery systems 
that have restricted their use as an antimicrobial in the design and manufacture of chronic 
indwelling devices.    SNP provides a thermally, chemically and photostable reservoir of metal 
atoms that are uniquely suited to polymer composite formation while remaining available for 
conversion to the active ionic compound upon exposure to physiological solutions. SNP show 
efficient antimicrobial property compared to other salts due to their extremely large surface area, 
which leads to better contact with microorganisms [31]. 
Our novel biomass medicated synthesis and concentration/purification method allows for 
the synthesis of high purity, biocompatible, nanomaterial powders and colloidal solutions with 
tunable chemical properties. This SNP synthesis method produces metal nanoparticles with a 
size distribution from 25-75 nm. By careful choice of capping surfactants and 
bioresorbable/biocompatible stabilizing agents the silver ion release profile and particle 
dissolution rate can be predictably modified, allowing fine control of the antimicrobial efficacy 
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and particle lifetime in a physiological environment.  Additionally, by combining SNP’s into a 
bioresorbable, thin film coatings we will create a further degree of freedom for influencing 
particle longevity and silver ion release. In an effort to explore the breadth of silver ion release 
capabilities, NanoHorizons Inc. (State College, PA) prepared alginate based wound dressings 
with varying compositions of SNP and compared silver release to commercially available, silver 
containing dressings (Fig 1.1). In the case of alginate substrates NanoHorizons found a nearly 
linear relationship between silver nanoparticle content and silver elution rate, which allowed us 
to tune the silver release profile to both match and exceed each of the commercially devices, thus 
demonstrating the degree of control which nanomaterial enhanced biocompatible composites can 
afford device designers.  
 
Figure 1.1. Comparison of silver elution vs. time from commercially available silver 
containing dressings and SNP-alginate composite dressings 
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Based on this method, several commercial compounds have been developed and are in 
use in a variety of applications such as in hospital beds, medical foams, apparel and industrial 
textiles, sanitary ceramics and cleaning products.  
1.2 Method Selection 
The applicability of silver nanomaterials in various applications has attracted considerable 
recent interest. Some of their applications include being used as catalysts [59-63], as 
photosensitive components [64], in photocatalysis [65-68], in chemical analysis [69], as probes 
for enhanced Raman spectroscopy, and as biocidal agents [70-78].  The large surface area and 
higher reactivity of SNP when compared to bulk solids allow the particles to exhibit 
extraordinary chemical, physical and biological properties. With wide range of potential 
applications, it is not surprising that many authors have reported various methods to synthesize 
powder noble metals with improved morphology and smaller particle size. 
Some of the broadly categorized SNP syntheses include reduction methods, sol-gel 
processing, high pressure spurting, plasma synthesis, chemical vapor synthesis (CVS), and using 
microorganisms for the biosynthesis of metal NP. 
1.2.1 Reduction Methods 
SNP can be produced by reducing agents such Sodium tetrahydridoborate NaBH4[79], 
HCHO/NaOH/Na2CO3 [80]
 
, a combined reduction by tri-sodium citrate and formaldehyde 
sulfoxylate (SFS)
 
[81], tetrakis hydroxymethyl phosphonium chloride, citric acid hydrazine 
hydrate and solvents like DMF, Ethylene glycol.  
In 1979, silver sols were prepared by reduction of AgNO3 in an excess solution of 
NaBH4[82]. The solutions of silver salts were mixed rapidly and vigorously in order to aid 
monodispersity. Pyridine molecules adsorbed on the silver sol particles caused intense Raman 
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scattering. The sols were yellow and displayed a single visible extinction band near 400 nm by 
Raman spectra. The silver particles were substantially smaller than the wavelength of light and 
as indicated by transmission electron microscopy, the size of the particle diameter was roughly in 
the range 1-50 nm [79]. The sols were stable and there was no precipitation or change in color on 
standing for several weeks. 
Formaldehyde can also be used as a reducing agent for preparing nanoscale silver 
particles. In this synthesis, silver nitrate solution is used as the source of ion. The surfactant 
polyvinyl-pyrrolidone (PVP), a protective agent, is then added to AgNO3 and the metal is 
reduced using a formaldehyde solution. To increase the rate of the reaction, pH is increased by 
the addition of an alkaline solution consisting of NaOH and/or Na2CO3 which results in a faster 
reduction. This synthesis produces well-dispersed spherical shaped crystalline silver particle with 
7–20 nm size [80]. 
The stoichiometric reaction of this process can be summarized as follows: 
2Ag
+
  + HCHO + 3OH
−
                 2Ag + HCOO
− 
 +  2H2O   (1) 
2Ag 
+
  + HCHO +  OH
−
                     Ag + HCOOH +  1/2H2 (2) 
Direct large-scale synthesis of SNP is conducted by various reduction chemical methods 
but using mild reducing agent, such as formaldehyde SFS provides good particle morphology 
and results in fine silver powder [81].   
In this method for the synthesis of SNP, an aqueous solution of tri-sodium citrate was 
added to an aqueous solution of silver nitrate. The drop-wise addition of aqueous sodium 
formaldehyde sulphoxylate and continuous stirring at room temperature formed a dark gray 
precipitate, which can be filtered off, washed with methanol and dried. Scanning Electron 
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Microscopy (SEM) images indicate 30-50 nm spherical and agglomerated SNP due to the 
presence of surfactants/capping agents. 
1.2.2 Sol-gel Process 
The sol-gel technique is low temperature method for synthesizing organic or inorganic 
amorphous materials. It is based on hydrolysis and condensation reactions of organometallic 
compounds in alcohol solutions [83]. Many metal particles including gold [83-84], copper [85], 
platinum, palladium [86] and silver [87] have been prepared in glassy matrices by the sol-gel 
method. 
For the creation of stable silver metal nanoparticles, AgNO3 is dissolved in the precursor 
sol that contains TetraEthoxy OrthoSilane (TEOS) and Methyl- TriEthoxy OrthoSilane 
(MeTEOS). Soda lime glass slides can be added in the precursor sol and AgCl containing sol gel 
glasses are prepared.  When these films are heated to 600
0
C, stable silver metal nanoparticles are 
created that are 2-21 nm in size as calculated from X-ray diffraction [82]. This method produces 
large clusters of SNP of inconsistent size.    
1.2.3 Chemical Vapor Synthesis (CVS) 
Recently, CVS has become popular tool for producing highly pure, ultrafine and un-
agglomerated nano-crystalline powders. Many chemical vapor methods have been developed 
which take advantage of various conditions to prepare SNP. Some of the various CV methods 
include sonic-jet corona discharge [88-89], electrospray-assisted CVD process [90]
 
and 
supersonic nozzle expansion method [91]. 
In sonic-jet corona discharger method, sonic-jet corona ionizer is heated by an infrared 
furnace and an electric field is applied. Charged nanoparticles are deposited on the substrate 
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electrode in the CVD nanoparticle generator by the help of an electric field after ionized 
molecules are introduced in the furnace. 
The electrospray-assisted CVD reactors consist of an electrospray source, a tube-type 
CVD furnace and an electrostatic sampler. Liquids are supplied into the capillary by a high 
resolution syringe pump and a high voltage is applied to the capillary through a high DC voltage 
source. Electric current carried by electrospray and the stability of the spray is monitored 
visually, in this process changes in the voltage could result in multiple jets of the liquid. NPs 
were produced by the thermal decomposition of the precursor vapors in the reactor. 
Recently, supersonic nozzle expansion method (rapid decrease in temperature and 
density) with corona discharge ions was used for synthesizing SNP. In the particle formation 
step, the high cooling rate of condensable vapor results in a large supersaturation for the 
nucleation rate. The nucleation and growth of the SNP occurs after the expansion region in the 
supersonic nozzle, where corona discharge ions are applied, as the nuclei for nanoparticles, to 
impart charge and modulate agglomeration. 
Overall, CV methods produce NP from the vapor phase in a well controlled temperature 
zone of a hot wall reaction tube. These processes typically produce agglomerated NP due to their 
Brownian coagulation in the CVD reactor. Although latest CVD methods have produced 
nonagglomerated, smaller sized and charged nanoparticles [91]. 
1.2.4 Biological Approach 
With an increased demand to develop clean, nontoxic and environmentally friendly NP 
synthesis methods, many researchers have started looking at biological systems for inspirations 
[56]. There are many examples both in the plant and animal kingdom of unicellular and 
multicellular organisms that produce inorganic materials either intra- or extracellularly [92-93]. 
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Some of them include magnetotactic bacteria (synthesize magnetite nanoparticles)[94-95], 
diatoms (synthesize siliceous materials) [96-97], S-layer bacteria (produce gypsum and calcium 
carbonate layers) [98-99] and fungus Verticillium (synthesize aqueous Ag+ ions) [100]. 
The biological synthesis of silver-based 200 nm crystals in the periplasmic space of 
Pseudomonas stutzeri AG259 was reported in 1999 [36, 101]. This bacterium strain was 
originally isolated from silver mine[36]. In this method, the cells are cultured in the presence of 
high concentrations of silver salts. They are then harvested, fixed, distilled and polymerized. 
Ultrathin sections are stained and visualized under microscope.  
There are many other methods of synthesizing SNP including genetically engineered 
human L subunit ferritin [102], high pressure spurting[103], plasma spray methods [104], 
supercritical fluids (SCFs) [105] and etc. Although many of these methods have succeeded in 
synthesizing nonagglomerated, pure, small size and stable SNP, there still exists a room for 
improvement in the design of polymer based SNP synthesis.   
1.3 Characterization of Silver Nano Particles 
The inclusion of silver nanoparticles into biocompatible polymers presents us with the 
analytical challenge of characterizing thin film. Many analytical methods have been published to 
characterize and confirm the presence of nanoparticles in the polymers. These methods outline 
the chemical composition and physical characteristics of the nanomaterials [106].  
1.3.1 Atomic Force Microscopy (AFM) 
Initially, AFM was introduced as imaging tool [107] as it provides high resolution, three-
dimensional images and helps in detailing surface topography. Recently it has been widely used 
for the investigation of nanoparticle-doped materials and surface biofouling. It has also been 
used to examine nanoparticle deposition on silicon substrates, and the morphology of these 
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nanoparticles was studied [108]. Several publications have also used AFM to confirm the 
morphology and size distribution of silver nanoparticles [109]. It has several advantages terms of 
resolution, speed and ease of sample preparation when compared to other when compared to 
cryo-electron microscopy and X-ray crystallography techniques [110]. 
For our synthesis AFM has been used to determine the organization, shape and size of 
SNP. 
1.3.2 Transmission Electron Microscopy (TEM) 
TEM is also an analytical tool for determining the morphology and arrangement of 
nanoparticles comprised materials. Several studies have utilized TEM as a characterization 
method for different nanoparticles including SNP [111].  
Embedded SNP, in ultra thin specimen, can be visualized by TEM [112] and serves as 
one of our major characterization tools. It enables us to visualize and characterize the 
morphology and distribution of SNP embedded in the biocompatible polymer-based coatings.  
1.3.3 Scanning Electron Microscopy (SEM) 
SEM is also an analytical tool that uses a focused beam of high-energy electrons to 
generate a variety of signals at the surface of solid specimens. Unlike TEM, it allows the surface 
structure of the sample to be studied at high resolutions, enabling characterization of external 
morphology (texture), chemical composition, and crystalline structure and orientation of solid 
materials. 
Due to its high resolution we will use SEM to characterize and morphologically define 
the biocompatible/biogradable PLLA co-polymer antimicrobial bioscaffolds that will be tested 
against gram-positive and gram-negative bacteria. 
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1.3.4 UV-Visible Spectroscopy 
           UV-visible spectroscopy is a very simple and quick method for characterizing noble metal 
nanoparticles and is mostly used to confirm the presence of nanoparticles in a liquid. It is not 
capable of providing detailed information regarding NP size distribution when compared to 
microscopy based analysis techniques but is a semi-quantitative method for determining the 
presence and size distribution of NP. UV-Vis can also serve as an indicator of material 
deterioration and is a qualitative method for indicating the presence of nanoparticles in the 
polymer. 
The breadth of the UV-visible chromatogram peak, obtained from SNP, will indicate the size 
distribution of SNP but morphology has to be confirmed using different imaging methods. The 
sample preparation for this method is very simple and will enable us to monitor the effectiveness 
of the silver nanomaterial and adhesion of SNP to the biocompatible polymer. 
1.4 Silver Content Analysis 
Determining the silver content in these NP composites is critical to the design of effective 
antimicrobial coatings. The silver content of polymers is typically proportional to the ion elution 
rate and the content analysis will help in tuning the silver concentration to achieve maximum 
efficacy of the biocompatible/bioresorbable polymer-based coatings and scaffolds. Some of the 
methods that comply with our needs and are available to use are Thermogravimetric Analysis 
(TGA) and Inductively Coupled Plasma-Optical Emission Spectrometer (ICPOES).  
1.4.1 Thermogravimetric Analysis (TGA) 
TGA is commonly used in research and testing to determine the mass of inorganic and 
organic components in materials by measuring the characteristic of weight change of a material 
in relation to changes in temperature. Synthesized copper, silver and alumina nanocomposites 
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have been characterized by thermo gravimetric analysis to study the composition of the metal 
nanoparticles’ percentage contained in the polymer/composite [113]. The weight loss curve, after 
curve smoothing and other operations, can be used to find the point of deflection.  
For our SNPs, TGA serves as one of our major characterization tools to determine the 
percent of silver particles in the polymer. Additionally, TGA can also provide information 
related to the spatial conformation of the silver content and the chemical state of the Ag atoms in 
the SNP solution [114].  
1.4.2 Inductively Coupled Plasma Optical Emission Spectrometer (ICPOES) 
ICP-OES (Inductively Coupled Plasma-Optical Emission Spectrometer) is one of the 
most common analytical methods for determining silver content as it has high sensitivity, high 
precision, and capable of determining range of metals and several non metals at concentrations 
range from a several percent to ppb levels [115]. 
In this study, ICPOES analysis is used to monitor the release of SNP particles and ions 
from the biocompatible/bioresorbable polymer based coating after being treated with bacteria. 
The analysis enables us to quantify the release of SNP from the coatings in a time-based study 
and plot the release profile of SNP. 
1.5 Material Selection 
Increasingly during the past 40 years research in the field of biocompatible materials has 
been directed to the development and characterization of “bioerodible” or “bioresorbable” 
materials. These are materials which can be degraded and excreted from the body over an 
extended period of time ranging from days to years have and have been used in a variety of 
applications including medical device coatings [116] sutures and tissue scaffolds[117]  
A variety of “natural” (occurring in nature) and synthetic materials have been identified 
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or developed which broadly meet the criteria to be considered bioresorbable or bioerodible. 
Some of the broad categories include aliphatic esters, chitosan, aliginates, polyhydroxy acids and 
poly (tyrosine-carbonates)[118]. Of these compounds the material and chemical properties of 
aliphatic esters such as poly-L-lactic acid (PLLA), poly-L-glycolic acid (PLGA), make them of 
interest for orthopedic device applications.  The in-vivo degradation processes of these 
compounds have been well described and while there are some reports of the onset of late stage 
inflammation responses, these have been attributed to high molecular weight particles released 
from highly crystalline substrates [119-120].   
The accepted guidelines for the selection of an appropriate material include: that the 
material is broadly biocompatible and the polymer coating material must degrade and resorb at a 
controlled rate. For a tissue scaffold the polymer should also provide a suitable substrate for 
tissue regrowth and have regulatory approval or have the potential to gain approval [121]. 
Additionally, in the case of coatings for orthopedic implants the material must have the 
appropriate hardness, modulus and adhesion strength to survive the implantation procedures and 
use.
 
 1.5.1 Poly (L-lactide) 
There is a limited pool of biocompatible polymers that are also bioresorbable and can be 
used for chronic indwelling medical devices. Chitosan, PLLA, PLGA and collagen are few 
examples that qualify as potential substrates for our thin film coatings and bioscaffolds. 
Poly (L-lactide) (PLLA), aliphatic ester, has been widely used in the biomedical industry 
as a major component of biodegradable sutures, medical device coatings and bone fixation nails 
and screws [122]. The compound is well characterized and the degradation of PLLA is 
dominated by nonenzymatic hydrolysis of polymer chains catalyzed by carboxylic acid chain 
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ends of polymers.  This degradation process results in non-toxic monomers and oligomers of 
lactic acid [123].  The degradation rate of PLLA is dependent on the molecular weight of the 
polymer, typically high molecular weight PLLA has been used in orthopedic surgery [124]. For 
these reasons, PLLA has been selected as the polymer of choice in our study. PLLA of different 
molecular weights (~40,000 to 1000, 000) are commercially available. To create the composite 
PLLA thin film coatings and PLLA-PEG bioscaffolds we selected PLLA with average molecular 
weight of 100,000-150,000.
 
1.5.2 Polyethylene Glycol (PEG)  
Polyurethanes are a class of hydroxyl group containing polymers that consist of a chain 
of organic units joined by urethane. In recent years, biocompatible material research has been 
focused on using resorbable and degradable polyurethanes for tissue regeneration including 
cardiovascular repair, ligament reconstruction, cancellous bone regeneration, and drug delivery. 
Generally, polyurethanes are developed by labile moieties, such as caprolactone, lactides, 
hydroxybutyric acid, saccharide and amino acids that can be broken enzymatically or chemically 
by hydrolysis [125]. PEG’s chemical functionality, flexible hydrophilic chain, low toxicity and 
low immunogenicity [126-127], have made it an ideal option as one of the polymer constituents 
of PLLA-PEG co-polymer with novel SNP to be used as antimicrobial bioscaffolds [128]. 
1.6 References 
 
1. Council, P.H.C.C.H., Hospital-acquired infections in pennsylvania calendar year 2006. 
2008: Harrisburg PA. p. 97. 
 
2. Mody, L., et al., Indwelling Device Use and Antibiotic Resistance in Nursing Homes: 
Identifying a High-Risk Group. Journal of the American Geriatrics Society, 2007. 55: p. 
1921-1926. 
 
3. Brunetto, P.S. and K.M. Fromm, Antimicrobial coatings for implant surfaces. Chimia, 
2008. 62(4): p. 249-252. 
 18 
4. Kwakye-Awuah, B., et al., Antimicrobial action and efficiency of silver-loaded zeolite X. 
Journal of Applied Microbiology, 2008. 104(5): p. 1516-1524. 
 
5. Abedi, D., et al., Antimicrobial properties of acrylic fabrics dyed with direct dye and a 
copper salt. Textile Research Journal, 2008. 78(4): p. 311-319. 
 
6. Roe, D., et al., Antimicrobial surface functionalization of plastic catheters by silver 
nanoparticles. Journal of Antimicrobial Chemotherapy, 2008. 61(4): p. 869-876. 
 
7. Damm, C. and H. Munstedt, Kinetic aspects of the silver ion release from antimicrobial 
polyamide/silver nanocomposites. Applied Physics a-Materials Science & Processing, 
2008. 91(3): p. 479-486. 
 
8. Burkatovskaya, M., et al., Effect of chitosan acetate bandage on wound healing in 
infected and noninfected wounds in mice. Wound Repair and Regeneration, 2008. 16(3): 
p. 425-431. 
 
9. Raad, I., et al., Anti-adherence activity and antimicrobial durability of anti-infective-
coated catheters against multidrug-resistant bacteria. J. Antimicrob. Chemother., 2008. 
62(4): p. 746-750. 
 
10. Percival, S.L., P. Bowler, and E.J. Woods, Assessing the effect of an antimicrobial wound 
dressing on biofilms. Wound Repair and Regeneration, 2008. 16(1): p. 52-57. 
 
11. Lorente, L., et al., The use of rifampicin-miconazole - Impregnated catheters reduces the 
incidence of femoral and jugular catheter-related bacteremia. Infection Control and 
Hospital Epidemiology, 2008. 29: p. 1171-1175. 
 
12. Adair, C.G., et al., Implications of endotracheal tube biofilm for ventilator-associated 
pneumonia. Intensive Care Medicine, 1999. 25(10): p. 1072-1076. 
 
13. Jones, D.S., et al., Physicochemical Characterization of Hexetidine-Impregnated 
Endotracheal Tube Poly(vinyl Chloride) and Resistance to Adherence of Respiratory 
Bacterial Pathogens. Pharmaceutical Research, 2002. 19(6): p. 818-824. 
 
14. Olson, M.E., B.G. Harmon, and M.H. Kollef, Silver-Coated Endotracheal Tubes 
Associated With Reduced Bacterial Burden in the Lungs of Mechanically Ventilated 
Dogs. Chest, 2002. 121(3): p. 863-870. 
 
15. Johnson, J.R., M.A. Kuskowski, and T.J. Wilt, Systematic Review: Antimicrobial Urinary 
Catheters To Prevent Catheter-Associated Urinary Tract Infection in Hospitalized 
Patients. Ann Intern Med, 2006. 144(2): p. 116-126. 
 
16. Elliott, T.S.J., An update on antimicrobial central venous catheters. Journal of Hospital 
Infection, 2007. 65(Supplement 2): p. 34-38. 
 
 19 
17. Loertzer, H., et al., Use of Catheters With the AgION Antimicrobial System in Kidney 
Transplant Recipients to Reduce Infection Risk. Transplantation Proceedings, 2006. 
38(3): p. 707-710. 
 
18. Brandt, O., et al., Nanoscalic silver - a new silver composition with broad spectrum 
antimicrobial activity and less toxicological side effects than silver sulfadiazine. Journal 
of Investigative Dermatology, 2008. 128: p. S74-S74. 
 
19. Ruparelia, J.P., et al., Strain specificity in antimicrobial activity of silver and copper 
nanoparticles. Acta Biomaterialia, 2008. 4(3): p. 707-716. 
 
20. Lansdown, A.B.G., et al., Silver aids healing in the sterile skin wound: experimental 
studies in the laboratory rat. British Journal of Dermatology, 1997. 137(5): p. 728-735. 
21. Lansdown, A., Silver I: its antibacterial properties and mechanism of action. JOURNAL 
OF WOUND CARE, 2002. 11(4): p. 125-131. 
 
22. Sondi, I. and B. Salopek-Sondi, Silver nanoparticles as antimicrobial agent: a case study 
on E. coli as a model for Gram-negative bacteria. Journal of Colloid and Interface 
Science, 2004. 275(1): p. 177-182. 
 
23. Stobie, N., et al., Prevention of Staphylococcus epidermidis biofilm formation using a 
low-temperature processed silver-doped phenyltriethoxysilane sol-gel coating. 
Biomaterials, 2008. 29(8): p. 963-969. 
 
24. Sambhy, V., et al., Silver Bromide Nanoparticle/Polymer Composites:&nbsp; Dual 
Action Tunable Antimicrobial Materials. Journal of the American Chemical Society, 
2006. 128(30): p. 9798-9808. 
 
25. Darouiche, R., et al., A comparison of two antimicrobial-impregnated central venous 
catheters. Catheter Study Group. New England Journal of Medicine, 1999. 340(1): p. 1-
8. 
 
26. Greenfeld, J., et al., Decreased bacterial adherence and biofilm formation on 
chlorhexidine and silver sulfadiazine-impregnated central venous catheters implanted in 
swine. Critical Care Medicine, 1995. 23(5): p. 894. 
 
27. Tan, S., et al., Study on the structure and antibacterial activity of silver-carried zirconium 
phosphate. Materials Letters, 2008. 62(14): p. 2122-2124. 
 
28. Khare, M.D., et al., Reduction of catheter-related colonisation by the use of a silver 
zeolite-impregnated central vascular catheter in adult critical care. Journal of Infection, 
2007. 54(2): p. 146-150. 
 
29. Cowan, M.M., et al., Antimicrobial efficacy of a silver-zeolite matrix coating on stainless 
steel. Journal of Industrial Microbiology and Biotechnology, 2003. 30(2): p. 102-106. 
 20 
30. DRITCH, E., et al., Silver Nylon Cloth: In vitro and in vivo Evaluation of Antimicrobial 
Activity. The Journal of Trauma: Injury, Infection, and Critical Care, 1987. 27(3): p. 301. 
 
31. Rai, M., A. Yadav, and A. Gade, Silver nanoparticles as a new generation of 
antimicrobials. Biotechnology Advances, 2009. 27(1): p. 76-83. 
 
32. Klasen H, A historical review of the use of silver in the treatment of burns. Part I early 
uses. Burns, 2000. 30: p. 1-9. 
 
33. Rosenkra.Hs and H.S. Carr, SILVER SULFADIAZINE - EFFECT ON GROWTH AND 
METABOLISM OF BACTERIA. Antimicrobial Agents and Chemotherapy, 1972. 22(5): 
p. 367-&. 
 
34. Bragg, P.D. and D.J. Rainnie, EFFECT OF SILVER IONS ON RESPIRATORY-CHAIN 
OF ESCHERICHIA-COLI. Canadian Journal of Microbiology, 1974. 20(6): p. 883-889. 
 
35. Schreurs, W.J.A. and H. Rosenberg, EFFECT OF SILVER IONS ON TRANSPORT AND 
RETENTION OF PHOSPHATE BY ESCHERICHIA-COLI. Journal of Bacteriology, 
1982. 152(1): p. 7-13. 
 
36. Haefeli, C., C. Franklin, and K. Hardy, PLASMID-DETERMINED SILVER RESISTANCE 
IN PSEUDOMONAS-STUTZERI ISOLATED FROM A SILVER MINE. Journal of 
Bacteriology, 1984. 158(1): p. 389-392. 
 
37. Yamanaka, M., K. Hara, and J. Kudo, Bactericidal actions of a silver ion solution on 
Escherichia coli, studied by energy-filtering transmission electron microscopy and 
proteomic analysis. Applied and Environmental Microbiology, 2005. 71(11): p. 7589-
7593. 
38. Richards, R.M.E., ANTIMICROBIAL ACTION OF SILVER-NITRATE. Microbios, 1981. 
31(124): p. 83-91. 
 
39. Kjolseth, D., et al., COMPARISON OF THE EFFECTS OF COMMONLY USED 
WOUND AGENTS ON EPITHELIALIZATION AND NEOVASCULARIZATION. Journal 
of the American College of Surgeons, 1994. 179(3): p. 305-312. 
 
40. Sambhy, V., B.R. Peterson, and A. Sen, Multifunctional Silane Polymers for Persistent 
Surface Derivatization and Their Antimicrobial Properties. Langmuir, 2008. 24(14): p. 
7549-7558. 
 
41. Adams, A.P., E.M. Santschi, and M.A. Mellencamp, Antibacterial properties of a silver 
chloride-coated nylon wound dressing. Veterinary Surgery, 1999. 28(4): p. 219-225. 
 
42. Carr, H.S., Wlodkows.Tj, and Rosenkra.Hs, SILVER SULFADIAZINE - IN-VITRO 
ANTIBACTERIAL ACTIVITY. Antimicrobial Agents and Chemotherapy, 1973. 4(5): p. 
585-587. 
 
 21 
43. Gallant-Behm, C.L., et al., Comparison of in vitro disc diffusion and time kill-kinetic 
assays for the evaluation of antimicrobial wound dressing efficacy. Wound Repair & 
Regeneration, 2005. 13(4): p. 412-421. 
 
44. Muller, G. and A. Kramer, Biocompatibility index of antiseptic agents by parallel 
assessment of antimicrobial activity and cellular cytotoxicity. J. Antimicrob. Chemother., 
2008. 61(6): p. 1281-1287. 
 
45. Chaby, G., et al., Insuffisance rÈnale aiguÎ aprËs application topique de sulfadiazine 
argentique. Annales de Dermatologie et de VÈnÈrÈologie, 2005. 132(11, Part 1): p. 891-
893. 
 
46. Muller, M.J., et al., Retardation of wound healing by silver sulfadiazine is reversed by 
Aloe vera and nystatin. Burns, 2003. 29(8): p. 834-836. 
 
47. Simon, V., C. Albon, and S. Simon, Silver release from hydroxyapatite self-assembling 
calcium-phosphate glasses. Journal of Non-Crystalline Solids, 2008. 354(15-16): p. 
1751-1755. 
 
48. Balamurugan, A., et al., An in vitro biological and anti-bacterial study on a sol-gel 
derived silver-incorporated bioglass system. Dental Materials, 2008. 24(10): p. 1343-
1351. 
 
49. Dai, J.M., et al., Study on the color change resistant property of silver and zinc-loading 
zeolite 4A antibacterial agent. Journal of Inorganic Materials, 2008. 23(5): p. 1011-1015. 
 
50. Carrel, T., et al., Definitive cure of recurrent prosthetic endocarditis using silver-coated 
St. Jude Medical heart valves: a preliminary case report. J Heart Valve Dis, 1998. 7(5): 
p. 531-3. 
 
51. Kjaergard, H., et al., Recurrent endocarditis in silver-coated heart valve prosthesis. J 
Heart Valve Dis, 1999. 8(2): p. 140-2. 
 
52. Benn, T.M. and P. Westerhoff, Nanoparticle Silver Released into Water from 
Commercially Available Sock Fabrics. Environmental Science & Technology, 2008. 
42(11): p. 4133-4139. 
 
53. Wang, H., et al., Preparation of silver nanoparticles by chemical reduction method. 
Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2005. 256(2-3): p. 
111-115. 
 
54. Sun, Y. and Y. Xia, Shape-Controlled Synthesis of Gold and Silver Nanoparticles, in 
Science. 2002. p. 2176-2179. 
 
 22 
55. Wu, R.-T. and S.L.-C. Hsu, Preparation of highly concentrated and stable suspensions of 
silver nanoparticles by an organic base catalyzed reduction reaction. Materials Research 
Bulletin, 2008. 43(5): p. 1276-1281. 
 
56. Mukherjee, P., et al., Fungus-mediated synthesis of silver nanoparticles and their 
immobilization in the mycelial matrix: A novel biological approach to nanoparticle 
synthesis. Nano Letters, 2001. 1(10): p. 515-519. 
 
57. Raffi, M., et al., Studies of the growth parameters for silver nanoparticle synthesis by 
inert gas condensation. Journal of Materials Research, 2007. 22: p. 3378-3384. 
 
58. Vigneshwaran, N., et al., Silver-protein (core-shell) nanoparticle production using spent 
mushroom substrate. Langmuir, 2007. 23(13): p. 7113-7117. 
 
59. Claus, P. and H. Hofmeister, Electron microscopy and catalytic study of silver catalysts: 
Structure sensitivity of the hydrogenation of crotonaldehyde. Journal of Physical 
Chemistry B, 1999. 103(14): p. 2766-2775. 
 
60. Sun, T. and K. Seff, SILVER CLUSTERS AND CHEMISTRY IN ZEOLITES. Chemical 
Reviews, 1994. 94(4): p. 857-870. 
 
61. Verykios, X.E., F.P. Stein, and R.W. Coughlin, OXIDATION OF ETHYLENE OVER 
SILVER - ADSORPTION, KINETICS, CATALYST. Catalysis Reviews-Science and 
Engineering, 1980. 22(2): p. 197-234. 
 
62. Haneda, M., et al., Infrared study of catalytic reduction of nitrogen monoxide by propene 
over Ag/TiO2-ZrO2. Catalysis Today, 1998. 42(1-2): p. 127-135. 
 
63. Goncharova, S.N., E.A. Paukshtis, and B.S. Balzhinimaev, SIZE EFFECTS IN 
ETHYLENE OXIDATION ON SILVER CATALYSTS - INFLUENCE OF SUPPORT AND 
CS PROMOTER. Applied Catalysis a-General, 1995. 126(1): p. 67-84. 
 
64. Hailstone, R.K., COMPUTER-SIMULATION STUDIES OF SILVER CLUSTER 
FORMATION ON AGBR MICROCRYSTALS. Journal of Physical Chemistry, 1995. 
99(13): p. 4414-4428. 
 
65. Sclafani, A., M.N. Mozzanega, and P. Pichat, EFFECT OF SILVER DEPOSITS ON THE 
PHOTOCATALYTIC ACTIVITY OF TITANIUM-DIOXIDE SAMPLES FOR THE 
DEHYDROGENATION OR OXIDATION OF 2-PROPANOL. Journal of Photochemistry 
and Photobiology a-Chemistry, 1991. 59(2): p. 181-189. 
 
66. Tada, H., et al., Ag nanocluster loading effect an TiO2 photocatalytic reduction of bis(2-
dipyridyl)disulfide to 2-mercaptopyridine by H2O. Langmuir, 2000. 16(7): p. 3304-3309. 
 
 23 
67. Tada, H., K. Teranishi, and S. Ito, Additive effect of sacrificial electron donors on 
Ag/TiO2 photocatalytic reduction of bis(2-dipyridyl)disulfide to 2-mercaptopyridine in 
aqueous media. Langmuir, 1999. 15(20): p. 7084-7087. 
 
68. Sclafani, A. and J.M. Herrmann, Influence of metallic silver and of platinum-silver 
bimetallic deposits on the photocatalytic activity of titania (anatase and rutile) in organic 
and aqueous media. Journal of Photochemistry and Photobiology a-Chemistry, 1998. 
113(2): p. 181-188. 
 
69. Pal, T., GELATIN - A COMPOUND FOR ALL REASONS. Journal of Chemical 
Education, 1994. 71(8): p. 679-681. 
 
70. Olson, M.E., et al. Healing of porcine donor sites covered with silver-coated dressings. 
2000: Taylor & Francis As. 
 
71. Aymonier, C., et al., Hybrids of silver nanoparticles with amphiphilic hyperbranched 
macromolecules exhibiting antimicrobial properties. Chemical Communications, 
2002(24): p. 3018-3019. 
 
72. Alt, V., et al., An in vitro assessment of the antibacterial properties and cytotoxicity of 
nanoparticulate silver bone cement. Biomaterials, 2004. 25(18): p. 4383-4391. 
 
73. Balogh, L., et al., Dendrimer-silver complexes and nanocomposites as antimicrobial 
agents. Nano Letters, 2001. 1(1): p. 18-21. 
 
74. Melaiye, A., et al., Silver(I)-imidazole cyclophane gem-diol complexes encapsulated by 
electrospun tecophilic nanofibers: Formation of nanosilver particles and antimicrobial 
activity. Journal of the American Chemical Society, 2005. 127(7): p. 2285-2291. 
 
75. Lee, D., R.E. Cohen, and M.F. Rubner, Antibacterial properties of Ag nanoparticle 
loaded multilayers and formation of magnetically directed antibacterial microparticles. 
Langmuir, 2005. 21(21): p. 9651-9659. 
 
76. Podsiadlo, P., et al., Layer-by-layer assembly of nacre-like nanostructured composites 
with antimicrobial properties. Langmuir, 2005. 21(25): p. 11915-11921. 
 
77. Baker, C., et al., Synthesis and antibacterial properties of silver nanoparticles. Journal of 
Nanoscience and Nanotechnology, 2005. 5(2): p. 244-249. 
 
78. Sun, R.W.Y., et al., Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective 
activities toward HIV-1 infected cells. Chemical Communications, 2005(40): p. 5059-
5061. 
 
79. Heard, S.M., et al., THE CHARACTERIZATION OF AG SOLS BY ELECTRON-
MICROSCOPY, OPTICAL-ABSORPTION, AND ELECTROPHORESIS. Journal of 
Colloid and Interface Science, 1983. 93(2): p. 545-555. 
 24 
80. Chou, K.S. and C.Y. Ren. Synthesis of nanosized silver particles by chemical reduction 
method: Elsevier Science Sa. 
 
81. Khanna, P.K., et al., Water based simple synthesis of re-dispersible silver nano-particles. 
Materials Letters, 2007. 61(16): p. 3366-3370. 
 
82. Zayat, M., D. Einot, and R. Reisfeld, In-situ formation of AgCl nanocrystallites in films 
prepared by the sol-gel and silver nanoparticles in silica glass films. Journal of Sol-Gel 
Science and Technology, 1997. 10(1): p. 67-74. 
 
83. Katayama, Y., M. Sasaki, and E. Ando. THERMAL AND PHOTOCHEMICAL 
FORMATION OF SMALL GOLD COLLOIDS IN SOL-GEL FILMS. 1994: Elsevier 
Science Bv. 
 
84. Gacoin, T., et al., COMPLEXED METAL-CLUSTERS IN ORGANICALLY MODIFIED 
OXIDE MATRICES. Chemistry of Materials, 1993. 5(8): p. 1150-1156. 
 
85. Mennig, M., M. Schmitt, and H. Schmidt. Synthesis of Ag-colloids in sol-gel derived 
SiO2-coatings on glass: Kluwer Academic Publ. 
 
86. Kozuka, H. and S. Sakka. FORMATION OF SILICA-GELS COMPOSED OF 
MICROMETER-SIZED PARTICLES BY THE SOL-GEL METHOD. 1994: Amer 
Chemical Soc. 
 
87. Hinsch, A. and A. Zastrow. THE PRODUCTION OF SMALL COLLOIDAL SILVER 
PARTICLES IN THIN SIO2 SOL-GEL GLASS LAYERS. 1992: Elsevier Science Bv. 
 
88. Adachi, M., S. Tsukui, and K. Okuyama, Nanoparticle formation mechanism in CVD 
reactor with ionization of source vapor. Journal of Nanoparticle Research, 2003. 5(1-2): 
p. 31-37. 
 
89. Adachi, M., M. Kusumi, and S. Tsukui, Ion-induced nucleation in nanoparticle synthesis 
by ionization chemical vapor deposition. Aerosol Science and Technology, 2004. 38(5): 
p. 496-505. 
 
90. Nakaso, K., et al., Synthesis of non-agglomerated nanoparticles by an electrospray 
assisted chemical vapor deposition (ES-CVD) method. Journal of Aerosol Science, 2003. 
34(7): p. 869-881. 
 
91. Jung, J.H., H.H. Park, and S.S. Kim, Effects of corona discharge ions on the synthesis of 
silver nanoparticles by a supersonic nozzle expansion method. Journal of Vacuum 
Science & Technology B, 2007. 25(1): p. 169-174. 
 
92. Simkiss, K.a.W., K.M., Biomineralization; Cell Biology and Mineral Deposition. 1989: 
Academic Press. 337. 
 25 
93. Mann, S., Biomimetic Materials Chemistry. 1996, New York: Cambridge: VCH 
Publishers. 
 
94. Spring, S., K.L. Scheifer, Diversity of Magnetotactic Bacteria. System. Appl. Microbiol, 
1995. 18: p. 147-153. 
 
95. Dickson, D.P.E. Nanostructured magnetism in living systems. 1999: Elsevier Science Bv. 
 
96. Mann, S., MOLECULAR TECTONICS IN BIOMINERALIZATION AND BIOMIMETIC 
MATERIALS CHEMISTRY. Nature, 1993. 365(6446): p. 499-505. 
 
97. Oliver, S., et al., LAMELLAR ALUMINOPHOSPHATES WITH SURFACE PATTERNS 
THAT MIMIC DIATOM AND RADIOLARIAN MICROSKELETONS. Nature, 1995. 
378(6552): p. 47-50. 
 
98. Pum, D. and U.B. Sleytr, The application of bacterial S-layers in molecular 
nanotechnology. Trends in Biotechnology, 1999. 17(1): p. 8-12. 
 
99. Sleytr, U.B., et al., Crystalline bacterial cell surface layers (S layers): From 
supramolecular cell structure to biomimetics and nanotechnology. Angewandte Chemie-
International Edition, 1999. 38(8): p. 1035-1054. 
 
100. Mandal, D., et al., The use of microorganisms for the formation of metal nanoparticles 
and their application. Applied Microbiology and Biotechnology, 2006. 69(5): p. 485-
492. 
101. Klaus, T., et al., Silver-based crystalline nanoparticles, microbially fabricated. 
Proceedings of the National Academy of Sciences of the United States of America, 1999. 
96(24): p. 13611-13614. 
 
102. Kramer, R.M., et al., Engineered protein cages for nanomaterial synthesis. Journal of the 
American Chemical Society, 2004. 126(41): p. 13282-13286. 
 
103. Chandra, R., et al., Synthesis and TEM study of nanoparticles and nanocrystalline thin 
films of silver by high pressure sputtering. Nanostructured Materials, 1999. 11(8): p. 
1171-1179. 
 
104. Karthikeyan, J., et al., Plasma spray synthesis of nanomaterial powders and deposits. 
Materials Science and Engineering a-Structural Materials Properties Microstructure and 
Processing, 1997. 238(2): p. 275-286. 
 
105. Chih, Y.W. and W.T. Cheng, Supercritical carbon dioxide-assisted synthesis of silver 
nano-particles in polyol process. Materials Science and Engineering B-Solid State 
Materials for Advanced Technology, 2007. 145(1-3): p. 67-75. 
 
106. Weir, E., et al., The use of nanoparticles in anti-microbial materials and their 
characterization. Analyst, 2008. 133(7): p. 835-845. 
 26 
107. Gaboriaud, F. and Y.F. Dufrene, Atomic force microscopy of microbial cells: Application 
to nanomechanical properties, surface forces and molecular recognition forces. Colloids 
and Surfaces B-Biointerfaces, 2007. 54(1): p. 10-19. 
 
108. Qi, L.F., et al., Preparation and antibacterial activity of chitosan nanoparticles. 
Carbohydrate Research, 2004. 339(16): p. 2693-2700. 
 
109. Xu, J., et al., Synthesis and optical properties of silver nanoparticles stabilized by gemini 
surfactant. Colloids and Surfaces a-Physicochemical and Engineering Aspects, 2006. 
273(1-3): p. 179-183. 
 
110. Davies, E., et al., Ultra-high resolution imaging of DNA and nucleosomes using non-
contact atomic force microscopy. Febs Letters, 2005. 579(7): p. 1702-1706. 
 
111. Kim, J.H., et al., Effect of the polymer matrix on the formation of silver nanoparticles in 
polymer-silver salt complex membranes. Journal of Polymer Science Part B-Polymer 
Physics, 2006. 44(8): p. 1168-1178. 
 
112. Sambhy, V., et al., Silver bromide nanoparticle/polymer composites: Dual action tunable 
antimicrobial materials. Journal of the American Chemical Society, 2006. 128(30): p. 
9798-9808. 
 
113. Gao, Y., et al., Evidence for the monolayer assembly of poly(vinylpyrrolidone) on the 
surfaces of silver nanowires. Journal of Physical Chemistry B, 2004. 108(34): p. 12877-
12881. 
 
114. Andic, Z., et al., The synthesis of ultrafine and nanocomposite powders based on copper, 
silver anal alumina. Kovove Materialy-Metallic Materials, 2006. 44(3): p. 145-150. 
 
115. Wagatsuma, K., Application of modulation techniques to atomic emission spectrometry 
with inductively-coupled radio-frequency plasma and radio-frequency glow discharge 
plasma. Applied Spectroscopy Reviews, 2002. 37(2): p. 223-245. 
 
116. Bergsma, J.E., et al., LATE DEGRADATION TISSUE-RESPONSE TO POLY(L-
LACTIDE) BONE PLATES AND SCREWS. Biomaterials, 1995. 16(1): p. 25-31. 
 
117. Hutmacher, D.W., Scaffolds in tissue engineering bone and cartilage. Biomaterials, 
2000. 21(24): p. 2529-2543. 
 
118. Middleton, J.C. and A.J. Tipton, Synthetic biodegradable polymers as orthopedic 
devices. Biomaterials, 2000. 21(23): p. 2335-2346. 
 
119. da Cruz, A., et al., Evaluation of physical–chemical properties and biocompatibility of a 
microrough and smooth bioactive glass particles. Journal of Materials Science: Materials 
in Medicine, 2008. 19(8): p. 2809-2817. 
 27 
120. Bergsma, J., et al., Biocompatibility of intraosseously implanted predegraded poly 
(lactide): an animal study. Journal of Materials Science: Materials in Medicine, 1996. 
7(1): p. 1-7. 
 
121. Vert, M., Degradability of polymeric scaffolds in Tissue Engineering. 
 
122. Gombotz, W.R. and D.K. Pettit, BIODEGRADABLE POLYMERS FOR PROTEIN AND 
PEPTIDE DRUG-DELIVERY. Bioconjugate Chemistry, 1995. 6(4): p. 332-351. 
 
123. Abe, H., et al., Thermal degradation processes of end-capped poly(L-lactide)s in the 
presence and absence of residual zinc catalyst. Biomacromolecules, 2004. 5(4): p. 1606-
1614. 
 
124. Ikarashi, Y., T. Tsuchiya, and A. Nakamura, Effect of heat treatment of poly(L-lactide) on 
the response of osteoblast-like MC3T3-E1 cells. Biomaterials, 2000. 21(12): p. 1259-
1267. 
 
125. Zhang, C.H., N. Zhang, and X.J. Wen, Synthesis and characterization of biocompatible, 
degradable, light-curable, polyurethane-based elastic hydrogels. Journal of Biomedical 
Materials Research Part A, 2007. 82A(3): p. 637-650. 
 
126. Moffat, K.L. and K.G. Marra, Biodegradable poly(ethylene glycol) hydrogels crosslinked 
with genipin for tissue engineering applications. Journal of Biomedical Materials 
Research Part B-Applied Biomaterials, 2004. 71B(1): p. 181-187. 
 
127. Lee, J.H., H.B. Lee, and J.D. Andrade, BLOOD COMPATIBILITY OF POLYETHYLENE 
OXIDE SURFACES. Progress in Polymer Science, 1995. 20(6): p. 1043-1079. 
 
128. Wang, M., et al., Synthesis and characterization of PLLA-PLCA-PEG multiblock 
copolymers and their applications in modifying PLLA porous scaffolds. European 
Polymer Journal, 2007. 43(11): p. 4683-4694. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
CHAPTER 2. BIOCOMPATIBLE/ BIORESORBABLE POLYMER BASED 
SILVER COATINGS FOR CHRONIC INDWELLING MEDICAL 
DEVICES 
2.1 Introduction 
The chronic indwelling medical devices market is rapidly expanding and the use of these 
devices is often complicated by infections with biofilm-forming microbes that are resistant to 
various antimicrobial agents. Several antimicrobial agents have been synthesized for various 
applications including use in acute indwelling devices but the need of industrially relevant, 
biocompatible, cost-effective and highly concentrated antimicrobial agents for chronic 
indwelling devices remains.  
Biofilms are formed when bacteria excrete glue-like substance composed of a matrix of 
excreted polymeric compounds called exopolysaccharide (EPS). This provides bacteria a 
generalized method to adhere broad spectrum of materials including, metals, polymers and 
medical implants. To combat the biofilm reduction, a variety of active and passive strategies 
have been employed to impart antimicrobial properties to the materials used in the construction 
of indwelling devices including; antibiotics [1-2], inorganic salts [3-4], inorganic nanomaterials 
[5-6] and organic compounds [7-8].While these strategies have produced satisfactory results for 
acute indwelling devices such as; wound dressings [9], central venous catheters[10] and 
endotracheal tubes [11-13]; none of these approaches to incorporating an antimicrobial has 
yielded an optimized solution for chronic indwelling device environments. Many indwelling 
medical devices now incorporate traditional antibiotics and/or inorganic antimicrobial 
compounds to reduce the risk of infection associated with implantation. Several of these agents, 
which are associated with Healthcare Acquired Infections (HAI), have become increasingly 
resistant to traditional antibiotics. Bacterial stains such as Methicillin Resistant Staphylococcus 
Aureus (MRSA) and Vancomycin Resistant Enterococcus (VRE) have demonstrated broad 
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resistance to beta-lactam and glycopeptides based antibiotics and have been frequently 
associated with indwelling devices which have resulted in difficult to treat infections[14].   
Among the device based antimicrobial solutions that are currently commercially available 
silver, in a number of forms, has a successful history of safe and efficacious use against a broad 
spectrum of gram-positive and gram-negative microbial agents [15-17]. Various silver 
compounds have been used as antimicrobial agents in many healthcare related applications 
including; pathogen control, prophylaxis and therapeutic treatments. Salts [18-21], zeolites [22-
24] and thin film metal coatings [25] have demonstrated some utility as silver ion sources for 
medical devices, but concerns regarding cost, performance, bioavalibility, thermal and chemical 
stability, and safety have limited the broader adoption of these delivery vehicles in indwelling 
device applications. SNP provides a thermally, chemically and photostable reservoir of metal 
atoms that are uniquely suited to polymer composite formation while remaining available for 
conversion to the active ionic compound upon exposure to physiological solutions. It show 
efficient antimicrobial property compared to other salts due to their extremely large surface area, 
which leads to better contact with microorganisms [26].  
Recent advances in materials development have created silver in nano-form by various 
synthesis methods including different reduction methods [27-30], sol-gel process [31-35], CVS 
[36-39], CVD and biological approaches [40-51] but none comply the design requirements of 
being a robust, high purity, high yield synthesis that results in a chemically stable product being 
broadly compatible with bioresorbable/biocompatible thin film coatings.  
This study describes a SNP synthesis and purification method producing high purity, 
biocompatible, nanomaterial powders and colloidal solutions with tunable chemical properties 
and evaluates the applicability of a silver nanomaterial based antimicrobial compound as a 
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chemo-prophylactic agent in bioresorbable/biocompatible thin film coatings. We have 
determined the concentrations and contact times required for in vitro elimination of known titers 
of two model organisms, Staphylococcus aureus and Escherichia coli. Silver release rate and 
nanoparticle erosion as a function of particle concentration and thin film composition is 
characterized, along with bioresorbable films response to exposure to simulated physiological 
solution. The values obtained provide a baseline for in vivo cytotoxicity studies and is used to 
assess how silver nanoparticles can best be implemented in antimicrobial coatings for chronic 
indwelling devices. 
2.2 Experimental Setup  
 
Figure 2.1. Flow-chart of making SNP based PLLA composite coatings  
The overall process of synthesizing and characterizing antimicrobial silver nanomaterials 
is divided into four main parts; SNP synthesis, PLLA thin film coatings synthesis, determination 
of antimicrobial activity and evaluation of cytotoxicity (Fig. 2.1).  
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Our choice of SNP synthesis method is related to the design requirements for chronic 
indwelling medical device coatings. Based on design requirements we have selected one of the 
chemical reduction methods using formaldehyde as a reducing agent, in an alkaline NaOH 
solution to reduce AgNO3. This is a cost-effective and industry applicable reduction that occurs 
at room temperature. The addition of hydroxypropyl cellulose (HPC), a hydrophilic polymer 
derived from biomass, acts as a template, [52] stabilizes the particle and provides a mechanism 
for concentration and purification. HPC is a thermo-responsive compound and flocculates at 
elevated temperatures which facilitate synthesizing concentrated, highly pure and polymer 
compatible SNPs with increased permeability [53].  The thermally mediated flocculation and 
concentration step allows the bulk residual reaction by-products to be removed by serial 
pelleting, washing and resuspension. The synthesized SNP are characterized using widely used 
tools such as AFM [54-56], TEM [19, 57] and UV-Visible Spectroscopy to study the presence, 
morphology and size distribution of the particles. Other characterization tools including SEM 
and DLS are not used as the presence of HPC will introduce artifacts resulting in spurious 
morphological descriptions.  
In the second step we synthesize thin films coatings comprised of PLLA. A variety of 
“natural” (occurring in nature) and synthetic materials have been identified or developed which 
broadly meet the criteria to be considered bioresorbable or bioerodible. Some of the broad 
categories include aliphatic esters, chitosan, aliginates, polyhydroxy acids and poly(tyrosine-
carbonates [58]. PLLA was chosen for this study as in-vivo degradation processes has been well 
described and while there are some reports of the onset of late stage inflammation responses, 
these have been attributed to high molecular weight particles released from highly crystalline 
substrates [59-60]. Most studies have found the implants with PLLA, PLGA or copolymers to 
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result in very few rejections related complications [61-62]. The PLLA coatings were engineered 
to optimize thickness, substrate adhesion and concentration of the polymer to maximize the 
release of SNP. Adhesion testing of the PLLA coatings is also conducted to study their 
attachment to the glass surfaces in the presence and absence of APTS linker.   
The third process step focused on evaluating the antimicrobial efficacy of the 
nanocomposite coatings against the gram positive and gram negative bacteria; Escherichia coli 
and Staphylococcus aureus. The concentrations of SNP in the PLLA coatings were optimized to 
achieve four log reduction of viable CFU’s for each challenge organism. The ISO 22196 
standard protocol is chosen to increase the regulatory relevance of the testing and allow 
convenient comparisons to previously published results. The release of SNP from specimens to 
the bacterial solution is profiled by TGA and ICP-OES that quantifies the amount of released 
SNP in the polymer, and solution respectively 
   The last step in the experimental design involves varying the antimicrobial 
concentration of SNP in the PLLA coatings to quantify the cytotoxicity of the particles against 
HeLa cells. In the viability assay, HeLa are stained using Sytox Green and the results, from flow 
cytometer, presents the percentage of viable cells against the finalized, working and 
recommended concentration of SNP for the coatings.  
2.3 Experimental Approach 
2.3.1 Reagents 
Silver nitrate >99%, Hydroxypropyl cellulose (HPC) with an average molecular weight 
of 80,000, Sodium hydroxide (NaOH) at 98%, Formaldehyde 36.5-38%, Antifoam A 
concentrate, PLLA with average molecular weight of 100,000-150,000, 2-butanone HPLC grade 
≥99.7%, Brain Heart Infusion Agar (BHI), Nutrient Agar, Technical Agar, methanol, sodium 
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chloride, sodium phosphate, glutaraldehyde, sodium cacodylate, glycine, uranyl acetate and 
osmium tetroxide were purchased from Sigma Aldrich (Sigma Chemical Co, St Louis, MO) and 
used without further purification. Dulbecco’s Modified Eagle’s Medium-reduced serum 
(DMEM-RS), Dulbecco's Phosphate-Buffered Saline (D-PBS) with Ca
2+
 and Mg
2+
, Dulbecco's 
Phosphate-Buffered Saline (D-PBS) without Ca
2+
 and Mg
2+
 and Trypsin 0.25% were purchased 
from HyClone Laboratories, Inc. (Logan, UT). Opti-MEM Reduced-Serum Medium, Calcein-
AM and SYTOX Green were purchased from Invitrogen (Carlsbad, CA). Ethanol was purchased 
from Pharmco-Aaper and Commercial Alcohols (Brookfield, CT). 3-Aminopropyltriethoxysilane 
linker was purchased from Gelest, Inc. (Morrisville, PA) and 3% hydrogen peroxide (H2O2) was 
purchased from Humco (Texarkana, TX).  All solvents purchased were of analytical grade. 
2.3.2 Methods 
2.3.2.1 Microbiology Test Organisms 
Escherichia coli (ATCC 29522) and Staphylococcus aureus (ATCC 6538) are inoculated 
and grown in sterile 15-ml centrifuge tubes (BD Falcon, Franklin Lakes, NJ) containing Nutrient 
Agar and BHI broth respectively and incubated at 37ºC. 
2.3.2.2 Cell Culture 
HeLa cell  (American Type Culture Collection) are maintained in 25-cm
2
 flasks (BD 
Falcon, Franklin Lakes, NJ) with 5ml of Dulbecco’s Modified Eagle’s Medium-reduced serum 
(DMEM-RS) supplemented with 3% Fetal Bovine Serum (FBS) and incubated at 37ºC and 5% 
CO2. HeLa cells are plated at a density of 80,000 cells/cm
2
 in 12-well Tissue Culture plates 
(Falcon, Franklin Lakes, NJ) for active/direct exposure of SNP. For exposures to PLLA thin 
films, cells are plated with a 1 ml 2.6x10
6 
cell/ml cell solution in clear glass 60x15-mm glass 
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petri dishes (VWR International, LLC, West Chester, PA). Cells were allowed to adhere and 
grow for 24 hours prior to every exposure to SNP. 
2.3.2.3 Biomass Mediated SNP Synthesis  
35 ml of both 125 mM AgNO3 and 61.5 mM formaldehyde (HCOH) are added, by 
syringe pumps (KD Scientific 200,Holliston MA) to a pre dissolved solution containing 0.5 g 
NaOH, 0.3125 g HPC, 330 ml DI and 5ul antifoaming agent in RT. This results in the synthesis 
of 25-75 nm SNP. Purification is accomplished by thermal flocculation of the solution and 
removal of supernatant. The SNP-HPC solution is heated to 70-75
o
C under static conditions 
resulting in flocculation and precipitation. After precipitation the supernatant is removed and the 
pellet is resuspended in RT water. This process is repeated 4 times and the resulting pellet dried 
and ground yielding a ~98% pure SNP powder (Fig. 2.2). Samples are taken when 10 ml, 20 ml, 
30 ml and 35 ml of reactants have been added by syringe pumps to study the time-evolution of 
SNP over time by Genesys6 (Thermo Scientific, Madison WI) UV-Visible Spectrophotometer.  
 
Figure 2.2. Process flow diagram of the biomass mediated reduction and purification 
process. 
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2.3.2.4 Characterization of SNP 
For TEM characterization, 5 ul of 800 ppm SNP solution was pipetted on Carbon/Copper 
20-30 nm grids (EMS, Hatfield, PA), air dried and visualized with JEOL 100CX.  
The AFM analysis was conducted on Agilent 5500,  10 ul of 800ppm SNP solution was 
placed on freshly cleaved circular (1×1 cm
2
) pieces of mica (0001) (Ruby muscovite mica, S&J 
Trading Inc., Glen Oaks, NY). 
2.3.2.5 PLLA Thin Film Coatings 
A 1% PLLA polymer in butanone solution (RED = 0.44-0.48) is stirred for ½ hr at 75-
80°C until dissolved. The solution is cooled to RT with continuous stirring until the solution 
clouds. The butanone volume is maintained to keep the polymer stable. 100 ul of methanol 
containing varying concentrations of colloidal SNP is then added to 10 ml of PLLA polymer 
solution to create a dilution ladder. Cylindrical glass petri dishes, 60 mm in diameter and 25 mm 
in height, are treated with 2% γ-aminopropyltriethoxysilane (APTS) coupling agent for 4-5 
minutes and excess solution is removed from the substrate. The substrates are then cured at 
100
o
C for 2-3 mins. 10 mL of SNP containing PLLA solution is poured into the treated dish and 
solvent is allowed to evaporate for 24 hrs at RT in a fume hood. After evaporation the substrates 
with dried coatings are then extracted in DI water for 24 hrs with DI exchanges every 12 hrs, 
followed by incubation at 50°C for 24 hours to extract residual solvent. The coated substrates are 
sterilized by autoclaving before antimicrobial and cytotoxicity experiments. 
Two PLLA coatings with SNP concentrations of 700 ppm and 5000 ppm along with two 
controls, coatings with No SNP and No SNP with 100 ul of HPC, were characterized with 
Cambridge Stereoscan 260 SEM (Cambridge Scientific Instruments, Cambridge, UK) at 25 kV 
to study the thickness, surface characteristics of the coatings. Each sample is mounted on 
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aluminum stubs with either Tubecote or colloidal graphite and sputter coated with a gold-
palladium film in an Edwards S-150 sputter coater (Edwards High Vacuum Co. International, 
Wilmington, Massachusetts, USA) to image the surface morphology. 
Also, TGA was used to quantify the amount of SNP in the polymer. For TGA analysis, 
PLLA samples with varying concentrations of SNP (600 ppm-5000 ppm) are cast on glass Petri 
dishes (as above) and then samples of PLLA films are analyzed with a TGA 2950 (TA 
Instruments New Castle, Delaware) by heating them from RT to a final temperature of 400
o
C at 
a rate of 15
 o
C/min.  
2.3.2.6 Antimicrobial Activity 
Prior to testing, methanol was extracted from the dried coating by soaking in DI water for 
24 hrs while exchanging DI water every 12 hrs. This was followed by incubation at 50 °C, in 
air for 24 hours to extract residual solvent. The coated substrates are sterilized by autoclaving 
before antimicrobial and cytotoxicity experiments. 
The quantitative antimicrobial testing on Staphylococcus aureus and Escherichia coli was 
conducted according to the ISO 22196 test methods. Briefly, 300 ul of the inoculated bacterial 
cultures were exposed to either duplet or triplet coatings for every SNP concentration for 24 hrs.  
A coating without SNP was also included in the dilution ladder as a control for each test 
organism to measure the efficacy of the coatings. 
The antimicrobial activity was calculated using the following equation: 
R = (U t − U0) − (At − U0) = Ut − At         where;  
R     is the antibacterial activity; 
U0      is the average of the common logarithm of the number of viable bacteria, in cells/cm
2
,   
       recovered from the untreated test specimens immediately after inoculation; 
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Ut       is the average of the common logarithm of the number of viable bacteria, in cells/cm
2
,  
       recovered from the untreated test specimens after 24 hr; 
At   is the average of the common logarithm of the number of viable bacteria, in cells/cm
2
, 
recovered from the treated test specimens after 24 hr. 
2.3.2.7 Silver Release from PLLA Coating 
To determine the silver release profile, TGA and ICP-OES are used to study the release 
of SNP to determine the mass of silver released upon exposure to PBS. A coating containing 700 
ppm SNP was exposed to 7ml PBS solution for 7 days. 4-5 mg polymer samples were collected 
with sterile forceps and 1 ml PBS solution was collected everyday for TGA and ICP-OES 
analysis respectively. A no-SNP containing control sample was also run to compare the results 
obtained. 
For TGA, the PLLA samples were analyzed with TGA 2950 (TA Instruments New 
Castle, Delaware) by heating them from RT to a final temperature of 400
o
C at a rate of 15
 
o
C/min. For ICP-OES, the released SNP in 1 ml PBS solution was digested with 1 ml nitric acid 
and diluted to a final volume of 10 ml with acidified water.  
2.3.2.8 Cytotoxicity Experiments/Direct Exposure 
HeLa cell are passaged (Appendix A.1.b) and 600 ul cell solution, 80,000 cells/cm
2
, is 
added to 12-well Tissue Culture plates and incubated for 24 hrs at 37ºC with 5% CO2. 2 ul of 
varying concentrations of SNP (100 ppm-1 ppb), silver nitrate (100 uM-0.1 nM), dissolved in 
both DMEM and OPT-MEM, and 2 ul of H2O2, positive control, are added to 600 ul cell solution 
in each well for the next 24 hrs. After 24 hr exposure, the cell solution and sample are aspirated 
and 600 ul of D-PBS (with Ca
2+
 and Mg
2+
) is added along with 2 ul of 10 nM SYTOX Green for 
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5 mins. The stain and DPBS solution is then aspirated and the cells are washed with 400 ul 
DPBS. The wells are then imaged using Nikon FL microscope. 
2.3.2.9 Electron Microscopy Analysis of SNP Exposed HeLa  
The HeLa cells are exposed to 100 ppm SNP and visualized by TEM to study the 
mechanism of SNP uptake by the cells. HeLa cells were maintained by serial passaging 
(Appendix A.1.b).  For testing 600 ul cell solution of  2.6x10
6 
cell/ml is added to 12-well Tissue 
Culture plates and incubated for 24 hrs at 37ºC with 5% CO2. 2 ul of 100 ppm SNP concentration 
solution, cytotoxic threshold concentration for direct exposure, section 2.4.5, is added to 600 ul 
cell solution for the next 2 hrs. 600 ul of Trypsin is added for 10 min to detach the cells from the 
wells, followed by addition of 1 ml of DMEM. The 1.2 ml detached cells solution was then 
centrifuged at 1800 rpm for 5 minutes and suspended in 1 ml of D-PBS. 
The 1ml of cell suspension was aspirated into a syringe containing an equal volume of 
4% glutaraldehyde in 0.1M sodium cacodylate buffer, pH 7.2.  The fluid was then diluted with 6 
ml of 2% glutaraldehyde in 0.1M buffer and drawn into a 10 ml syringe with a Swinney filter 
holder (Millipore Corporation, Billerica, MA) fitted with a 13 mm diameter 8 um pore 
polycarbonate filter. The filtered cell solution was fixed for 4 hours. The solution was then 
washed 4 times in 0.1 M cacodylate buffer containing 0.02 M glycine, post-fixed in 2% osmium 
tetroxide for 1 hr, rinsed in water, and bloc stained in 0.5% uranyl acetate in the dark for 1 hr, 
rinsed in water and dehydrated in ethanol series. The filter paper was removed from the syringe, 
infiltrated in 1:1 ethanol:LR White resin (Electron Microscopy sciences, Hatfielf, PA) solution 
for 1 hr,  infiltrated in pure LR White for 1 hr, and embedded in LR White overnight at 60
o
C.  
80-90 nm ultra-thin sections were cut on Ultracut E microtome (Reichert-Jung, Austria) for TEM 
analysis. The TEM sections were mounted on coated copper grids (Electron Microscopy 
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sciences, Hatfield, PA), stained with Reynolds lead citrate, and examined in a JEOL 100CX 
transmission electron microscope operated at 80 kV. 
2.3.2.10 Cytotoxicity Experiments on PLLA Films 
The HeLa cells are passaged (Appendix A.1.b) using sterile protocols and 1 ml confluent 
cell solution, 2x10
6
 cell/ml, is added to the 1% wt PLLA thin films of varying concentration of 
SNP (700 ppm-5000ppm) and incubated for 24 hr at 37ºC with 5% CO2. After the 24 hr 
exposure, the detached cells are aspirated and 1ml of D-PBS (with Ca
2+
 and Mg
2+
) is added to 
the petri dishes. The cells are harvested from the coatings by adding 1 ml of Trypsin for 10 min 
followed by addition of 1 ml of DMEM. The 4 ml detached and attached cells are pooled and 
centrifuged at 1800 rpm for 5 minutes. The solution is aspirated and the cell pallet is re-
suspended in 1 ml D-PBS and stained by adding 5 ul of 500 uM Sytox Green for 15 mins. The 
cell solution is centrifuged again at 1800 rpm for 5 minutes and fixed in 250 ul of 1% 
paraformaldehyde (PFA) solution (Appendix A.2.b). The experiment also included negative and 
positive controls.  A 600 ul cell solution is incubated in 12-well plate for 24 hrs.  After the 24 hr, 
2 ul of H2O2 is added to the well for positive control for further 24 hrs. After the 24 hr exposure, 
the detached cells are aspirated and 600 ul of D-PBS (with Ca
2+
 and Mg
2+
) is added to the wells. 
The cells are harvested from the wells by adding 600 ul of Trypsin for 10 min followed by 
addition of 600 ul of DMEM. The 2400 ul detached and attached cells are pooled and 
centrifuged at 1800 rpm for 5 minutes. The solution is aspirated and the cell pallet is re-
suspended in 1 ml D-PBS and stained by adding 5 ul of 500 uM Sytox Green for 15 mins. The 
cell solution is centrifuged again at 1800 rpm for 5 minutes and fixed in 250 ul of 1% 
paraformaldehyde (PFA) solution (Appendix A.2.a). 
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The viability of fluorescently labeled cells is quantified by BD FACSCalibur cytometer 
(Franklin Lakes, NJ). 
2.3.2.11 Adhesion Testing  
The SiOx substrates were modified with a self assembling monolayer (APTS) to improve 
adhesion (as above). The 3-Aminopropyltriethoxysilane (APTS) (Fig. 2.3(a)) acts as an 
intermediate linker that forms a discreet monolayer on SiOx and presents an amino group for 
interacting with the carbonyl (C=O) groups of PLLA (Fig 2.3(c)). Coatings with and without 
APTS linker are tested to quantify the adhesion of the coatings on the glass surfaces.  
The tensile strength test is a rapid and reliable method for evaluating the practical 
adhesion of thin film coatings on substrates. Double-sided 3M™ 4026 tape (St. Paul, MN) is 
applied to the coatings cast on the glass surfaces, and pulled with Instron 8841(Norwood, MA)  
at a speed of 2 mm/sec for 20 mm, while the holder, with glass petri dish coated with PLLA 
nanocompsoite, is held immobile (Fig. 2.4(a)). The Instron applies tensile force to the coating 
and the force cell records the force needed to separate the coating at the coating- glass interface 
(Fig. 2.4 a, b and c) . The adhesive links the coating and the metal pull-arm which is linked to the 
Instron force cell with Poly (methyl methacrylate) (PMMA) (Fig. 2.4 a and c). The test was 
conducted on PLLA coatings attached to the glass surface with and without the APTS linker to 
quantify the impact of the APTS linker on adhesion strength. A no-coating control sample was 
also analyzed to compare the results obtained.  
2.4 Results and Discussion 
2.4.1  Biomass Mediated SNP Synthesis 
The time-evolution study was performed during the synthesis process to study the 
progression and behavior of synthesized SNP as reactants were added via syrings pump. 1 ml 
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samples were collected from the final beaker when 10 ml, 20 ml, 30 ml and 35 ml of the 
reactants had been added. These four samples clearly showed the successful progression of the 
synthesis reaction which  produces concentrated silver particles with distinct color change from 
greyish-black 10 ml sample to dark grey 35 ml sample. When the final sample was diluted with 
DI water, the solution had a goldenish brown color indicating the prescence of SNP. The three 
different characterization tools also confirmed the making of poly dispersed SNP. The Genesys 6 
UV-Vis spectrometer was used to evaluate all 4 time-evolution based samples and indicated a 
clear silver surface plasmon resonance peak at 415 nm confirming the formation of silver 
particles with the reduction of silver nitrate with formaldehyde (Fig 2.5) . It should also be noted 
that with the addition of reagents, plasmon resonance peak was not shifted right, as may be 
expected with increase in the particle size, while the absorbance value increased from 0 to 2.5. 
With this observation, we conclude that using this method we synthesize monodispersded SNP 
and with the progression of the process we concentrate the final solution with monodispersed 
SNP instead of synthesizing diferent sized SNPs. 
 
Figure 2.3. (a) Molecular structure of 3-Aminopropyltriethoxysilane linker. (b) Detailed 
mechanism and chemistry behind linker-substrate bond (c) the overall linking mechanism 
of glass surface, APTS linker and the PLLA coatings 
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Figure 2.4. (a) General set-up for testing the adhesion of PLLA coatings on the glass 
surface. (b) PLLA coating attached to the double-sided tape. (c) Tensile testing on Instron 
with PMMA holders securing the coating with metal grips. 
 
Figure 2.5. UV-Vis Spectrum of SNP indicating the time-evolution of the synthesis process. 
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The SNP morphology was analyzed by TEM using a JOEL CX100 electron microscope. 
Fig 2.6 show the importance and potential function of HPC aside from being used as the 
stabilizing agent and thermo-responsive compound. The figure includes 3 images (Fig 2.6 a, b 
and c) with increasing magnification. The lighter colored areas of the particles (Fig 2.6 (c)) are 
likely HPC, rich regions encapsulating more dense, and darker, silver laden regions. The HPC 
molecule acts as the precursor substrate attracting silver nitrate through hydrogen bond [63], and 
SNP are formed as formaldehyde reduction takes place. The HPC substrate acts to evenly 
disperse the silver nitrate and thus produces more monodispersed and highly concentrated SNPs 
compared to other reduction based synthesis methods. This SNP synthesis method produced 
metal nanoparticles with a size distribution from 25-75 nm, as determined by TEM.  
 
 
    Figure 2.6. Three TEM images of SNP with increasing magnification (a) 20K (b) 160K 
(c) 250K. The scale bar is given with each image. 
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 AFM was used to assess the z-directional dimension of the SNPs.  The height of SNPs 
was measured by samples placed on freshly cleaved circular pieces of pieces of mica (0001) and 
a standard soft cantilever with spring constants ranging from 0.05 to 0.1 N/m, was used for 
imaging in contact mode. The root mean square (RMS) height of SNP was measured to be 114 
nm and is not in agreement with TEM images of the SNPs. (Fig 2.7) 
 
Figure 2.7. AFM images of SNP. The images show that the height of these SNP is around 
150 nm when measured with the scale bar 
The overall characterization by using spectroscopy and EM based analytical tools 
confirmed the synthesis of concentrated, non-agglomerated and biocompatible SNP. The novel 
synthesis of encapsulating SNP in a biocompatible cellulose derivative ensured the potential use 
of SNP for the reduction of biofilm in chronic indwelling medical devices.   
2.4.2 PLLA Thin Film Coatings 
2.4.2.1 Characterization of PLLA Film  
The PLLA nanocpmposite thin films were cast on glass petri dishes in an effort to  
optimize the thickness, substrate adhesion silver release. SEM images of PLLA nanocomposite 
demonstrate that the casting process yield uniform thin films approximately 50 um thick (Fig. 2.8 
e and f) with a corresponding volume of 9.82 mm
3
. The composite surface morphology is greatly 
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influenced by the HPC content of the coatings. The SNP are stabilized with HPC and the bulky 
molecular structure of HPC introduces artifacts in the morphology of the composites. Comparing 
the surfaces of 700 ppm with 5000 ppm films (Fig 2.8 c and e) it can be seen that the surface of 
later coating is smoother and more homogenous than that of film containing 700 ppm SNP. 
Similarly, while comparing the surfaces of PLLA coating without SNP (Fig 2.8 (a)) and a PLLA 
coating with HPC (Fig 2.8 (b)), the surface of PLLA coating with HPC is smoother and more 
homogenous than that of PLLA coating without HPC. Based on these SEM images, the particle 
to volume ratio for 700 ppm and 5000 ppm coatings is 3.98 x 10
16
 and 2.84x 10
17
 SNP particles 
per millimeter cube of the film. 
 
Figure 2.8. SEM images of 1% PLLA thin film coatings. (a) Surface of PLLA coating with 
No SNP. (b) Surface of PLLA coating with No SNP and 100 ul HPC. (c) Surface of PLLA 
coating with 700 ppm SNP. (d) Surface of PLLA coating with 5000 ppm SNP. (e) Cross-
section of PLLA coating with 700 ppm SNP  (f) Cross-section of PLLA coating with 5000 
ppm SNP. 
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The TGA results of the amount of SNP present in the coatings are shown in Appendix 
B.1. The lower detection limit of TGA 2950 system is higher than the amount of SNP present in 
the PLLA coatings and statistically valid readings were not obtained by this characterization 
method. 
2.4.2.2 Concentration of PLLA Films 
The cast coating process for PLLA biocompatible/bioresorbable coatings was optimized 
to form thin films with good adhesion and release of silver ion. Solvents for casting had to be 
chosen cafefully to reduce potential cytotoxic and  antibacterial side effects. Also, the solvent 
had to be miscible with the polar solvents used to dissovle powder SNP. Methanol dissolves 
HPC stabilized SNP adequetly resulting in a collidal supension of metal particles, additionally 
residual ethanol can be easily removed from the cast polymer by DI washes. Many publications 
used chloroform [64] as the potential solvent for PLLA but the presence of Cl
-
 could act as 
residual antimicrobial agent resulting in false positive results for our applications or conversly 
could react with free silver cation forming insoluble chloride salts. Agrawal and etc. lists many 
potential solvents of PLLA based on RED values and we selected the methyl ethyl ketone (2-
butanone) as the solvent for dissolving PLLA [65]. The solvent has a solubility limitation and 
only 1%wt PLLA polymer can be dissolved in butanone. After optimizing the concentration of 
PLLA catsing conditions were defined. The differences in thermal expansion coefficients of the 
film and the glass petri dishes can cause mechanical stress. By casting and bonding the films on 
the glass surface the extrinsic stress was eliminated as they both are constrained in the lateral 
direction and the stresses develop equally. This results in uniform and adherent coatings. Fig 2.9 
shows the difference between optimized coating (Fig 2.9 (b)) and coatings cracking under tensile 
stress conditions. The coating (Fig 2.9 (a)) was casted by filling the maximum amount of 
 47 
solution 60 mm x15 mm petri dishes could hold while coating (Fig 2.9 (b)) was casted by 
pouring 10 ml of 1% PLLA solution.  
 
Figure 2.9. Difference between two coatings with same polymer concentration (1%) but 
different polymer amounts. (a) Coatings buckling due to thin film stress (b) Optimized 
coating. 
2.4.2.3 Drying Conditions for PLLA Films 
Next, the drying conditions were optimized to achieve uniform coatings for its effective 
performance. The PLLA cast coatings dry really fast and perfect conditions have to be 
maintained to facilitate their drying procedure. The solvent was evaporated under fume hood 
and different conditions were evaluated to study the drying process. Fig 2.10 shows the 
difference in coatings homogeneity and consistency of the coatings. Coating (Fig 2.10(a)) was 
dried at RT with open vent to speed up the drying process which resulted in non-homogeneous 
and hard, white low stress coating. On the other hand, drying at RT with negligible air flow 
aides in formation of low stress polymer (Fig 2.10 (b)). 
2.4.2.4 Treatment of PLLA FiLms  
Prior to testing, methanol was extracted from the dried coating by soaking in DI water for 
24 hrs while exchanging DI water every 12 hrs. This is followed by incubation at 50 °C, in air 
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for 24 hours to extract residual solvent. The coated substrates are sterilized by autoclaving before 
antimicrobial and cytotoxicity experiments. 
 
Figure 2.10. Difference between two coatings with same polymer concentration (1%) but 
different drying conditions. (a) Coatings “hardening” under the influence of air flow (b) 
Optimized coating. 
2.4.3 Antimicrobial Activity 
 After sterilizing the coatings, two microorganism Escherichia coli and 
Staphylococcus aureus were tested against varying amounts of SNP embedded in the coatings to 
create a dilution ladder. They were chosen as they are the two most commonly occurring strains 
of bacteria in Healthcare Acquired Infections (HAI) and both strains have demonstrated resistant 
to many antibiotics including amoxicillin and methicillin respectively [66]. A standard  
procedure, detailed in the ISO 22196 protocol was followed for microbial challenge assays.  The 
target was to generate a 3-5 log reduction in the number of viable bacteria. The colony forming 
unit (CFU) values of the controls are 2.25x10
7
CFU/ml for S.aureus and 5.54 x105 CFU/ml for 
E.coli. The percentage bacterial reduction of S.aureus and E.coli for the various experimental 
groups can be seen in Fig 2.12. The results indicate S.aureus is more resistant to silver 
inactivation when compared E.coli, this may be related to the thick peptidoglycan layer of gram 
positive bacteria. At 700 ppm SNP, we obtain a 3 log reduction, 99.9%, for S.aureus (Fig 2.11 
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(a)) and 4 log reduction for E.coli, 99.9% (Fig 2.11 (b)). There is also a clear lower SNP 
concentration threshold of ~500 ppb after which the reduction of bacteria is negligible (Fig 2.11). 
The percentage bacterial reduction drops from 41.7% to 7.8% for S.aureus (Fig 2.11 (a)) and 
50% to 2.58% for E.coli (Fig 2.11 (b)). 
 Fig 2.12 shows the decrease in bacterial colonies across the SNP concentration and it can 
be seen that at 700 ppm the CFU values decrease from 2.25x10
7
CFU/ml to 4.10 x10
4 
for 
S.aureus (Fig 2.12 (a)) and from 5.54 x105 CFU/ml to 5.60 x101 for E.coli (Fig 2.12 (b)). 
  Based on these consistent results we can recommend 700 ppm as the antimicrobial 
concentration for the PLLA based SNP containing chronic indwelling medical device thin film 
cast coatings.  
We also tested the effects of using APTS linker on the antimicrobial activity of the SNP 
composite coating against both organisms. For a fixed SNP concentration of 500 ppb, two 
coatings are prepared; one with and the other without the APTS linker. There is no apparent 
difference in bacteriocidal activity of the two groups (Fig 2.13 and Fig 2.14). The percentage 
difference is 0.08 % and 2.7% for S.aureus and E.coli respectively (Fig 2.13 a and b). The initial 
CFU values are 2.25x10
7 
CFU/ml for S.aureus and 5.54 x105 CFU/ml for E.coli. The bacterial 
count remains 1.20x10
7 
CFU/ml for S.aureus while it changes from 2.77 x105 to 5.08 x105 
CFU/ml for E.coli on APTS and non-APTS coatings (Fig 2.14 a and b). These changes in CFU 
values for S.aureus and E.coli are statistically insignificant as the p-values, 0.24 and 0.056 
respectively, are higher than either 5% or 1% significance level. With minimal and 
insignificance difference, it can be concluded that using APTS linker to improve the adherence 
of PLLA coatings does not have substantial effect on the viable bacteria and the data collected in 
Fig. 2.11 and Fig 2.12 is solely due to the presence of SNP in the coatings. 
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Figure 2.11. Graphs representing the percent bacterial reduction when exposed to varying 
concentrations of SNP. (a) 4 log reduction of S.aureus (b) 3 log reduction E .coli 
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Figure 2.12. Graphs representing the reduction in bacterial colonies when exposed to 
varying concentrations of SNP. (a) for S.aureus (b) for E .coli 
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Figure 2.13. Graphs representing the percent bacterial reduction with the presence and 
absence of APTS linker. Both coatings have a fixed SNP concentration of 500 ppb. (a) 
Comparison between coatings for S.aureus (b) Comparison between coatings for E .coli. 
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Figure 2.14.  Graphs representing the reduction in bacterial colonies with the presence and 
absence of APTS linker. Both coatings have a fixed SNP concentration of 500 ppb. (a) for 
S.aureus (b) for E .coli. 
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The extraction of residual solvents from the PLLA coatings proved to be an essential step 
to generate reproducible antimicrobial results. The biocidal of these residual solvents is 
demonstrated in Fig 2.15 and Fig 2.16.  There was a difference of 17.9 % and 8.84% for S.aureus 
and E.coli exposed coatings when comparing the pre-treated and post-treated coatings 
respectively (Fig 2.15). This difference can be appreciated while comparing the difference is 
bacterial counts. The bacterial count decreases from 6.25x10
6 
to 2.58x10
6 
CFU/ml for S.aureus 
and 1.66 x10
5
 to 1.17 x10
5
 CFU/ml for E.coli on pre-treated and post-treated coatings (Fig 2.16). 
It is likely that these residual solvents would also be toxic to mammalian cells.  
Based on the results demonstrated in Fig 2.11, Fig 2.12 and Fig 2.13 we concluded that 
an antimicrobial concentration of 700 ppm meets the design requirement of reducing the count of 
viable bacterial CFU’s by 3-5 log. Also, the addition of APTS improves the adhesion of the 
coatings to the surface without impacting antimicrobial efficacy. 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Graphs representing the percent bacterial reduction for pre-treated and post-
treated coatings. Both coatings have a fixed SNP concentration of 200 ppm. (a) Comparison 
between coatings for S.aureus (b) Comparison between coatings for E .coli. (Fig. contd.) 
(a) 
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Figure 2.16. Graphs representing the reduction in bacterial colonies for pre-treated 
and post-treated coatings. Both coatings have a fixed SNP concentration of 200 ppm. (a) for 
S.aureus (b) for E .coli. (Fig. contd.) 
(b) 
(a) 
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 2.4.4 Silver Release Profile  
 The antimicrobial and bacterial reduction performance of these coatings is based on the 
efficiency of silver release from the polymer. Determining the rate of silver release with respect 
to time and correlating these results with bacteriocidal performance will allow the generation of 
design heuristics for the composite coatings Fig. 2.8.  
 TGA was used to analyze a 700 ppm SNP polymer samples over a period of 6 days to 
determine the mass of silver released upon exposure to bacteria.  The TGA results of the amount 
of SNP present in the coatings are shown in Appendix B.2. The lower detection limit of TGA 
2950 system is higher than the amount of SNP present in the PLLA coatings and therefore 
statistically valid results were not obtained by this characterization method. 
The release of SNP from and ions from the biocompatible/bioresorbable polymer based 
coating after being soaked in DPBS is measured by ICPOES and shown in Fig. 2.17. This 
analysis enables us to quantify the release of SNP from the coatings in a time-based study. It can 
be seen that a total of 506 ppb SNP is released after 7 days. The PLLA coating plays an 
important role in controlling the amount of released SNP below the high cytotoxicity threshold 
(b) 
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of 100 ppm (Fig 2.18) making the embedded SNP safe to be used in chronic indwelling medical 
device coatings.   
 
Figure 2.17: Release of SNP from the PLLA coatings over a period of 7 days. The release 
was measured by ICPOES 
2.4.5 Cytotoxicity Experiments/Direct Exposure 
Our initial experiments examined the cytotoxic threshold of SNP and silver nitrate when 
directly exposed to the cells. HeLa cells, a cervical cancer derived line, were chosen for these 
experiments. The HeLa were passaged using sterile protocols and exposed to SNP and silver 
nitrate concentrations ladder ranging from 1 ppb to 100 ppm and 0.1 nM to 100 uM 
(approximately 0.017 ppb to 17 ppm) respectively. The silver nitrate results were compared to 
SNP because it has long history of use for reducing the transmission of infection from mother to 
child during birthing. [67]. The study also conducted to compare the cytotoxicity of SNP and 
silver nitrate in the presence or absence of serum. The DMEM media contains naturally 
occurring proteins closely resembles the in vivo and physiological environments that will 
surround the coatings. The cells were stained using SYTOX
®
 Green which penetrates the 
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damaged plasma membranes of dead HeLa cells. The cytotoxicity of HeLa in DMEM is given in 
Figure 2.18 showing only the upper and lower limits along with positive and negative controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18. Sytox used to represent their cytotoxicity against SNP and silver nitrate in 
DMEM media. The 1
st
 image is Bright Field, 2
nd
 image is FITC and 3
rd
 is the overlay of 
first two images.(a)Negative control (Live HeLa) (b) Positive control (H2O2) (c) 100ppm 
SNP (d) 500ppb SNP (e)100ppb SNP (f) 100uM silver nitrate (17ppm) (g) 10nM silver 
nitrate (1.7ppm) (h) 1nM silver nitrate (0.017 ppm). The images are at 20x (Fig. contd.) 
(a) Negative control 
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These results indicate that for SNP and silver nitrate, 100 ppb and 0.017 ppb are the non-
cytotoxic threshold values respectively at which they are non-cytotoxic in serum-containing 
media. Silver nitrate has a lower cytotoxic threshold than SNP this is probably a result of its high 
solubility, low chemical and thermal stability which results in high concentration bolus of the 
ionic form.  
Experiments conducted in serum free media demonstrated a 100 fold decrease in 
cytotoxic thresholds for both SNP and AgNO3 while relative toxicity remained the same. The 
decreased cytotoxicity associated with serum containing environments is likely related to the 
chelation of silver ion through non-specific, protein-Ag ion interactions mediated by sulfhydryl 
and amine groups. In Fig 2.19 it can be seen that the lower limit of both SNP and silver nitrate 
increased from 100ppb to 1ppb and 1nM (0.017 ppb)  to 0.1 nM (0.0017 ppb) respectively.  
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Figure 2.19. Sytox used to represent their cytotoxicity against SNP and silver nitrate  in 
OPTI-MEM media. The 1
st
 image is Bright Field, 2
nd
 image is FITC and 3
rd
 is the overlay 
of first two images.(a)Negative control (Live HeLa) (b) Positive control (H2O2) (c) 100ppm 
SNP (d) 1ppb SNP (e)100uM silver nitrate (e) 0.1nM silver nitrate. The images are at 20x  
(a)Negative control 
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This in-vitro cytotoxicity testing, conducted similar physiological environment excepted 
during and after implantation allowed predictions to be made regarding the target SNP 
concentration required to cause cell death during their passive exposure to SNP.  
2.4.6 Electron Microscopy Analysis of SNP Exposed HeLa 
 TEM imaging was used analyze SNP interaction with the cellular membrane of live HeLa 
cells. The cell wall and intracellular structures of control HeLa can be seen in electron 
micrographs (Fig. 2.20 a and b) and the interaction of SNP with the cell membrane of treated 
cells can be seen in Fig 2.20 c and d. In the cells treated with 100 ppm SNP, cytotoxic threshold 
concentration for direct exposure (Section 2.4.5), the early stages of SNP endocytosis can be 
seen to be occurring in Fig 2.20 c and d. Additionally, potential sites of membrane compromise 
are associated with points where SNP have contacted the cell membrane. 
 
 
Figure 2.20. TEM images of 80-90 nm sections of HeLa cell when directly exposed to 100 
ppm SNP. (a) Live HeLa at a magnification of 3.3K (b) Live HeLa at a magnification of 
6.6K (c) Live HeLa exposed with 100 ppm SNP at a magnification of 26K. (d)  Live HeLa 
exposed with 100 ppm SNP at a magnification of 50K 
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2.4.7 Cytotoxicity Experiments on PLLA Films 
 After finding the effective antimicrobial concentration of SNP, the effects of various 
SNP concentrations were tested against HeLa to find the cytotoxicity range of PLLA coatings 
to recommend an efficacious and non-cytotoxic SNP concentration for industrial use. The 
PLLA coatings were casted as described in section 2.3.2.4 and autoclaved before the 
cytotoxicity experiments. The SNP concentration varied from 700 ppm to 5000 ppm (5 ppt) 
and the 24 hr exposure time was chosen for comparing results with the antimicrobial activity 
experiments. 
 The results in Fig 2.21 shows that HeLa are very resistant to SNP and have minimal 
effect of their viability even when exposed to high 5000 ppm SNP concentration via PLLA 
coating barrier. These results when compared with Fig 2.18 and Fig 2.19 show that having a 
PLLA thin film coating barrier reduces the effect of SNP on the cells and improve their 
biocompatibility in in vivo environments. With direct exposure, 100 ppm SNP proved 
cytotoxic to almost all the cells (Fig 2.18 (c)) while 5000 ppm SNP is the cytotoxic 
concentration for PLLA coatings with only 25.68% live HeLa cells (Fig 2.21). For the 
antimicrobial SNP concentration of 700 ppm 81.34% of HeLa cells are healthy and this 
concentration is both efficacious to microbes and non-cytotoxic to cells. 
 Figure 2.22 is a good representation of the results shown in Fig 2.21. The Forward 
Scatter (FSC) vs. Side Scatter (SSC) enabled us to look at the distribution of cells based upon 
size. As the Argon laser passed through the stream, light was deflected and refracted by the cells 
in the stream. Fig 2.22 (a) shows a typical closely tight and homogenous scatter plot of live cells 
while the scatter plot of Fig 2.22 (b) is shifted upward picking up the internal granularity and 
complexity in the cell debris of the dead HeLa cells. The R2 region is gated to include all the live 
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HeLa cell population while the M1 marker represents the percentage of dead cells. Also while 
comparing the positive and negative controls the clump outside the R1 regions grows in Fig 2.22 
(b) comparatively, indicating a good dead control sample. The percentage values of viable HeLa 
cells shown in Fig 2.21 are obtained from the M1 marker that distinguishes the dead and live cell 
region based on the intensity of Sytox Green signals collected at the PMT tubes. The Sytox 
Green vs. Counts graph is a comparative analysis in which the higher fluorophore signals 
represent a sample with compromised membrane while the lower fluorophore signals represent a 
sample with healthy cell membrane.  
 The Fig 2.22 (c, d and e) are of No SNP, 700 ppm and 5000 ppm (5 ppt) SNP 
concentration respectively and based on M1 marker and R2 region gate, drawn on the basis of 
controls; all three proves the non-cytotoxicity and biocompatibility of SNP and PLLA films to 
HeLa cells. 
 
Figure 2.21. Graphs representing the reduction of HeLa when exposed to varying SNP 
concentrations. It also includes positive and negative controls to better comparison and 
functioning of the Sytox Green fluorophore 
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Figure 2.22. The results obtained from flow cytometer. The first image is a Forward vs. 
Side scatter and the second image is the intensity of Sytox Green picked on the PMT tubes. 
(a) Negative control (Live HeLa with Sytox Green) (b) Positive control (dead HeLa with 
Sytox Green). (c)NO SNP (d) 700 ppm SNP (e) 5000 ppm SNP. 
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 2.4.8 Adhesion Testing  
 Strong adhesion of nanocomposite coatings is critical for the use in dwelling 
applications as delamination cracking could result in inflammation, immune response and/or 
tissue damage. The adhesion of the PLLA coatings in this study was greatly improved by 
addition of a self-assembling monolayer (SAM) of APTS linker (Fig 2.23). PLLA coatings cast 
without APTS SAM fails the standard scotch tape test and the tensile adhesion strength for this 
coating is assumed as 0 MPa. For the glass control, without PLLA coatings, the adhesion 
strength was measured to be 115.66 MPa, the force required to delaminate the double-sided tape 
from the bottom glass surface of a petri dish. The force required to induce delamination of the 
final engineered SNP PLLA composite coatings with addition of the SAM was measured as 
282.44 MPa (Fig 2.23). These results from sections 2.4.3 and 2.4.8 indicate the APTS SAM 
substantially improves the adhesion of PLLA coating to the oxide surfaces without negatively 
affecting the antimicrobial performance.  
Figure 2.23. Tensile strength of PLLA coating when attached to the surface with and 
without the APTS linker. 
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2.5 Conclusions 
 In this study we demonstrated a novel, cost effective and, concentration and biomass 
mediated method of synthesizing silver nanomaterial powders and colloidal solutions with 
tunable chemical properties. The resulting SNP are biocompatible, non-agglomerated, 
polydispersed, industrially relevant and of high purity. The 25-75 nm sized SNP are synthesized 
to be used in the chronic devices coatings as antimicrobial agents. The biocompatible/ 
bioresorbale PLLA based coatings are embedded with the SNP and it helps reduce the E.coli and 
S.aureus bacterial colonies by 99.9-99.99%. Based on the cytotoxicty and antimicrobial activity 
experiments we recommend a safe antimicrobial concentration of 700 ppm for these coatings 
that is both efficacious to the microbes (99.9-99.99% reduction) and non-cytotoxic (81.34% live 
HeLa) to the surrounding cells. Also, increasing the SNP concentration beyond 700 ppm will 
only have economic and aesthetic constrains as higher concentration does not have any better 
antimicrobial or cytotoxic results. The APTS adhesion linker increases the likeliness of these 
coatings to be used in actual chronic indwelling devices to help reduce the surgical site and 
Healthcare Acquired Infections (HAI) that immensely burdens the healthcare providers for 
services provided related to treating healthcare associated conditions. Clearly, further work is 
needed to conduct in vivo testing for chronic devices with SNP-containing PLLA coatings to 
study the antimicrobial and cytotoxicity results simultaneously. 
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CHAPTER 3. ANTIMICROBIAL BIOCOMPATIBLE BIOSCAFFOLDS 
FOR TISSUE REGROWTH 
3.1 Introduction 
With ever growing donor list and, an increasing rates of infection and foreign body 
reactions,  advancements in the field of biomaterial tissue engineering are vital to safe and 
successful repair of damaged tissues [1]. The shortage of tissues and organs for transplant 
medicine is on the rise across the globe. Nationally, nearly 1 million patients suffer from burn, 
1.25 million patients from pressure sores, 1.5 million patients from ailments requiring bone 
grafts, hip and other joint replacements and millions of patients from the loss of teeth and dental 
tissues. These alarmingly high numbers of patients will benefit from an engineered tissue 
solution which improves healing outcomes [1]. 
Increasingly tissue engineering research is being explored as a potential therapeutic 
modality to address limitations of tissue grafting and alloplastic tissue repair. The objective is to 
deliver bioactive materials such as cells, genes, drugs, peptides and/or proteins concomitantly 
with a degradable scaffold. The concept has grown to encompass stem-cell and gene-therapy 
approaches, with an objective of stimulating tissue repair or tissue replacement. The materials 
and porous architecture common in most scaffold designs perform a critical function in tissue 
regeneration by maintaining tissue volume, providing temporary mechanical stability, and 
delivering bioactive compounds (2-7).  
For nearly 40 years research in the field of biocompatible materials has been directed to 
the development and characterization of “bioerodible” or “bioresorbable” materials.(8)   These 
materials, which can be degraded and excreted from the body over an extended period of time, 
ranging from days to years, have found use in a variety of applications including sutures, tissue 
scaffolds and drug eluting devices. (9)  
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A variety of “natural” (occurring in nature) and synthetic materials have been identified 
or developed which broadly meet the criteria to be considered bioresorbable or bioerodible. 
Some of the broad categories include aliphatic esters, chitosan, aliginates, polyhydroxy acids and 
poly(tyrosine-carbonates). (10) Of these compounds the material and chemical properties of 
aliphatic esters such as poly-L-lactic acid (PLLA) and poly-L-glycolic acid (PLGA), make them 
of interest for many indwelling applications including wound care and orthopedic device 
applications.  The in-vivo degradation processes of these compounds have been well described 
and while there are some reports of the onset of late stage inflammation responses, these have 
been attributed to high molecular weight particles released from highly crystalline substrates. 
(11, 12)  Most studies have found the implants with PLLA, PLGA or copolymers to result in 
very few rejection related complications. (13, 14)    
Many publications have described the use fibrous scaffolds as a delivery vehicle for 
antimicrobial agents to treat number of infections such as periodontitis, osteomyelitis, 
tuberculosis and brucellosis (17-22). The PLLA based biocompatible bioscaffolds release 
encapsulated drugs in a predictable manner, related to the physico-chemical properties of the 
polymer and drug. Nanocomposite compounds provide a novel and flexible platform for 
incorporating drugs and other bioactive components into scaffolds. The large surface area and 
higher reactivity of nanoparticles when compared to bulk solids allow the particles to exhibit 
extraordinary chemical, physical and biological properties while the fundamentally small size 
minimizes the deleterious impacts traditionally associated with the formation of polymer 
composites containing a high volume fraction of solids.(23) 
This chapter evaluates the use of SNP nanocomposite PLLA-PEG co-block polymer 
bioscaffolds as a potential antimicrobial drug delivery system. We will determine the 
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concentrations and contact times required for the elimination, in vitro, of known titers of two 
model organisms, Staphylococcus aureus and Escherichia coli. The values obtained will provide 
baseline data to assess how SNP can best be implemented in nanocomposite bioscaffolds to 
create engineered, active antimicrobial tissue scaffolds.  
3.2 Experimental Approach 
3.2.1 Reagents 
Silver nitrate >99%, Hydroxypropyl cellulose (HPC) with an average molecular weight 
of 80,000, Sodium hydroxide (NaOH) at 98%, Formaldehyde 36.5-38%, Antifoam A 
concentrate, PLLA with average molecular weight of 100,000-150,000, Poly(ethylene glycol) 
with a relative molecular mass of 1900-2200, 1,4-Dioxane, 99.8%, Brain Heart Infusion Agar 
(BHI), Nutrient Agar, Technical Agar, sodium chloride and sodium phosphate  were purchased 
from Sigma Aldrich (Sigma Chemical Co, St Louis, MO) and used without further purification. 
Ethanol was purchased from Pharmco-Aaper and Commercial Alcohols (Brookfield, CT). All 
solvents purchased were of analytical grade. 
3.2.2 Methods 
3.2.2.1 Microbiology Test Organisms 
Escherichia coli (ATCC 29522) and Staphylococcus aureus (ATCC 6538) are inoculated 
and grown in sterile 15-ml centrifuge tubes (BD Falcon, Franklin Lakes, NJ) containing Nutrient 
Agar and BHI broth respectively and incubated at 37ºC. 
3.2.2.2 Biomass Mediated SNP Synthesis  
35 ml of both 125 mM AgNO3 and 61.5 mM formaldehyde (HCOH) are added, by 
syringe pumps (KD Scientific 200,Holliston MA) to a solution containing 0.5 g NaOH, 0.3125 g 
HPC, 330 ml DI and 5ul antifoaming agent at RT. This synthesis results in particles with a size 
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distribution ranging from 25-75 nm SNP, as determined by TEM. Purification is accomplished 
by thermal flocculation of the solution and removal of supernatant. The SNP-HPC solution is 
heated to 70-75
o
C under static conditions resulting in flocculation and precipitation. After 
precipitation the supernatant is removed and the pellet is resuspended in RT water. This process 
is repeated 4 times and the resulting pellet dried and ground yielding a ~98% pure SNP powder 
(Fig. 3.1). 1ml samples were taken when 10ml, 20ml, 30ml and 35ml of reactants have been 
added by syringe pumps to study the time/concentration-evolution of SNP. These samples were 
characterized using Genesys6 (Thermo Scientific, Madison WI) UV-Visible Spectrophotometer.  
 
Figure 3.1. Process flow diagram of the biomass mediated reduction and purification 
process. 
 
 
 77 
3.2.2.3 Characterization of SNP 
For TEM characterization, 5 ul of 800 ppm SNP solution was pipetted on Carbon/Copper 
20-30 nm grids (EMS, Hatfield, PA), air dried and visualized with JEOL 100CX.  
The AFM analysis was conducted on Agilent 5500,  10 ul of 800ppm SNP solution was 
placed on freshly cleaved circular (1×1 cm
2
) pieces of mica (0001) (Ruby muscovite mica, S&J 
Trading Inc., Glen Oaks, NY). 
3.2.2.4 Synthesis of Porous Bioscaffolds 
The 7% PLLA and PEG (50:50 by wt) are codissolved in dehydrated 1, 4-dioxane at 
50
o
C until transparent. Then 280 ul of DI water containing varying concentrations of colloidal 
SNP (800 ppm-500 ppb) are mixed into the PLLA/PEG solution. After cooling to RT, the 
solution is poured into a closed 4 cm long glass vial. The material is then frozen uni-directionally 
by immersing the test tube into a liquid nitrogen bath at a constant rate of 2.0 cm/hr. The cap is 
closed to prevent absorption of moisture. After freezing, the solidified sample is freeze-dried in 
Labconco FreeZone Plus (Kansas City, MO) at -5
o
C for 4 days. The honeycomb monolith 
structures are then soaked in ethanol for 3 days and the ethanol is replaced every 12 hr to ensure 
complete extraction of the PEG. After PEG extraction, the samples are again freeze-dried at -5
o
C 
to remove residual ethanol. 
3.2.2.5 Characterization of Monolith Bioscaffolds 
The solidified 4 cm long monolithic porous bioscaffolds were characterized with 
Cambridge Stereoscan 260 SEM (Cambridge Scientific Instruments, Cambridge, UK) at 25 kV.  
The top half of the bioscaffold is cut with a sharp razor blade both parallel and perpendicular to 
the direction of freezing to get hemi-cylindrical shaped samples. These samples were mounted 
on aluminum stubs with either Tubecote or colloidal graphite and sputter coated with gold-
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palladium in a Edwards S-150 sputter coater (Edwards High Vacuum Co. International, 
Wilmington, Massachusetts, USA) to better study the surface morphology of the bioscaffolds.  
3.2.2.6 Antimicrobial Activity 
The quantitative antimicrobial testing on Staphylococcus aureus and Escherichia coli is 
conducted according to the ISO 22196 test methods with few modifications. The bioscaffold is 
cut with a sharp razor blade both parallel and perpendicular to the direction of freezing to get 
hemi-cylindrical shaped samples. Scaffolds with varying SNP concentration were then 
inoculated with 300 ul of 2.3 x 10
8
 CFU/ml Staphylococcus aureus and Escherichia coli cultures 
for 24 hrs. The SNP concentrations examined ranged from 10 ppb-800 ppm and also included a 
control bioscaffold without SNP. The bacterial count is quantified by extracting the scaffolds 
with 1 ml PBS and plating serial dilutions of the bacterial solution on Nutrient Agar or BHI 
plates. 
 Based on the bacterial colony values obtained from plates, he antimicrobial activity can 
be calculated using the following equation: 
R = (U t − U0) − (At − U0) = Ut − At         where;  
R     is the antibacterial activity; 
U0      is the average of the common logarithm of the number of viable bacteria, in cells/cm
2
,   
       recovered from the untreated test specimens immediately after inoculation; 
Ut       is the average of the common logarithm of the number of viable bacteria, in cells/cm
2
,  
       recovered from the untreated test specimens after 24 hr; 
At   is the average of the common logarithm of the number of viable bacteria, in cells/cm
2
, 
recovered from the treated test specimens after 24 hr. 
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3.3 Results and Discussion 
3.3.1 Characterization of Monolith Bioscaffolds 
 
Figure 3.2 (a and b) shows a pair of SEM micrographs of a PLLA/PEG 50:50 blend after 
unidirectional freezing and freeze-drying. This cross-sectional view of the sample parallel to the 
direction of freezing provides an image of the honeycomb monolith structure, which has porous 
20 um microtubes aligned along the freezing direction.  
 
Figure 3.2. SEM images of PLLA/SNP monolith bioscaffolds. The samples are coated with 
gold-palladium and the surface morphology is studied under SEM. The microtubules are 
parallel and are 20 um wide. (a) SEM image at 86.1K (b) 20um wide channels shown at 
268K magnification. 
3.3.2 Antimicrobial Activity of SNP in Bioscafffolds  
The bioscaffold nanocomposite compounds were challenged with two microorganisms 
Escherichia coli and Staphylococcus aureus. . These strains were chosen as they are the two 
most commonly occurring strains of bacteria in Healthcare Acquired Infections (HAI) and have 
demonstrated resistance to several antibiotics including amoxicillin and methicillin respectively 
[17]. The dilution ladder of SNP composites was comparable to samples synthesized and 
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characterized in chapter 2. A bioscaffold without SNP was also included in the dilution ladder as 
a control for each test organism to measure the efficacy of the bioscaffolds. 
Fig 3.3 shows the percentage bacterial reduction across varying SNP concentration for  
S.aureus and E.coli on the top half of monolithic bioscaffold. It can be seen in Figure 3.3 that at 
every SNP concentration the reduction in viable S.aureus compared that of E.coli.  The thick 
peptidoglycan layer of S.aureus is believed to be interacting with the silver ions reducing the 
cytotoxic activity compared to E.coli.  At 800 ppm SNP, we obtain a 92.8% reduction for 
S.aureus (Fig 3.3 (a)) and 3 log (99.9%) reduction for E.coli (Fig 3.3 (b)).  
The antimicrobial activity varies with position along the axis of freezing within the 
structure. No significant bacterial reduction occurs while challenging the lower portion of 
monolithic bioscaffold samples. The SEM images show that the 20 um microtubes are more 
oriented tubular in the top half of the scaffold, compared to dendritic structure common in the 
lower portion of the structure. We hypothesize that the SNPs are excluded from the structure 
during precipitation in the bottom portion of the monolith and to the conditions which promote 
the more regular crystalline structure in the upper regions promote inclusion of the SNP.  
 While comparing these results to the cast materials reported on in chapter 2, these 
antimicrobial bioscaffolds have a different efficacy ladder. The cast PLLA coatings demonstrate 
a 3-4 log reduction at 700 ppm (Fig 2.12 a and b) while the unidirectionally precipitated 
scaffolds decrease the bacterial colonies by 92.5% and 99.9% at a higher concentration of 800 
ppm (Fig 3.3 a and b). Also, the lower antimicrobial threshold for the cast PLLA coatings is 
~500 ppb (Fig 2.12 a and b) while at this concentration the bioscaffolds are still efficacious, 
reducing the bacterial colonies of S.aureus and E.coli by 71.4% and 25% (Fig 3.3 a and b).  
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Figure 3.3. Graphs representing the percent bacterial reduction when exposed to varying 
concentrations of SNP on the top half of the bioscaffold. (a) S.aureus (b) E .coli 
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3.4 Conclusions 
In this study we demonstrated the fabrication of SNP containing nanocomposite 
scaffolds, with potential application is tissue regrowth and as drug eluting coatings. The 
biocompatible/ bioresorbale PLLA /PEG/SNP bioscaffolds composites demonstrated significant 
antimicrobial activity reducing the E.coli and S.aureus bacterial colonies by 92.5- 99.9% 
respectively. Based on the antimicrobial activity experiments we recommend an antimicrobial 
concentration of 800 ppm for these coatings that is efficacious to the microbes (92.5- 99.9% 
reduction). Clearly, further research is needed understand the mechanism of synthesis and to 
evaluate the physio-chemical properties of these materials. 
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CHAPTER 4. CONCLUSIONS AND FUTURE WORK  
 
The objective of this study is to synthesize and characterize polymer based, silver 
containing nanocomposite coatings, for use in chronic indwelling medical devices, and 
bioscaffolds that are both efficacious against microbes and non-cytotoxic to mammalian cells.  
For PLLA coatings we synthesized novel 25-75 nm sized SNP that are biocompatible, 
non-agglomerated, polydispersed, industrially relevant and of high purity to be used in the 
chronic devices coatings as antimicrobial agents. The biocompatible/ bioresorbale PLLA based 
coatings are embedded with the SNP and it helps reduce the E.coli and S.aureus bacterial 
colonies by 99.9-99.99%. Based on the cytotoxicty and antimicrobial activity experiments we 
recommend a safe antimicrobial concentration of 700 ppm for these coatings that is both 
efficacious to the microbes (99.9-99.99% reduction) and non-cytotoxic (81.34% live HeLa) to 
the surrounding cells. Also, increasing the SNP concentration beyond 700 ppm will only have 
economic and aesthetic constrains as higher concentration does not have any better antimicrobial 
or cytotoxic results. The APTS adhesion linker increases the likeliness of these coatings to be 
used in actual chronic indwelling devices to help reduce the surgical site and Healthcare 
Acquired Infections (HAI) that immensely burdens the healthcare providers for services 
provided related to treating healthcare associated conditions.  
We also demonstrated the fabrication of SNP containing nanocomposite scaffolds, with 
potential application is tissue regrowth and as drug eluting coatings. The biocompatible/ 
bioresorbale PLLA /PEG/SNP bioscaffolds composites demonstrated significant antimicrobial 
activity reducing the E.coli and S.aureus bacterial colonies by 92.5- 99.9% respectively. Based 
on the antimicrobial activity experiments we recommend an antimicrobial concentration of 800 
ppm for these coatings that is efficacious to the microbes (92.5- 99.9% reduction).  
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Although substantial progress was made toward designing successful cast coatings and 
scaffolds that demonstrate significant antimicrobial reduction other aspects of composite 
synthesis and behavior must be addressed before implementation of these coatings and 
bioscaffolds into therapeutic devices. The future work should address the following aspects:  
4.1 PLLA Coatings 
  Test the antimicrobial and cytotoxic behavior of PLLA nanocomposite coatings on 
simulated implantable device surfaces and compare the outcome with these results with 
previously published results from glass substrate materials in order to examine the impact of 
substrate composition on the physio-chemical properties the coatings. 
 Conduct the antimicrobial and cytotoxicity experiments in the presence serum 
containing media or mammalian blood to study the behavior of the PLLA coatings when used on 
cardiac or orthopedic devices. 
 Improve the adhesion testing method and conduct the testing on simulated implantable 
devices substrates. 
 Conduct an in-vivo analysis of the behavior of PLLA coatings by coating chronic 
indwelling devices and implanting in the devices in mammalian models to study the composites 
efficacy and biocompatibility.   
4.2 PLLA:PEG Bioscaffolds 
 Conduct EM analysis on bioscaffolds to study the distribution of SNP in the scaffolds 
per volume or area to better comprehend the distribution of SNP in the scaffolds.  
 Explore the impact of composite composition and synthesis conditions on 
nanomaterial distribution. 
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 Repeat the antimicrobial testing and vary the SNP concentrations above 800 ppm and 
below 500 ppb.  
 Study the effects of adding varying concentration of SNP on the mechanical strength 
and porosity of bioscaffolds through SEM and tensile testing. 
 Conduct mechanical test on various PLLA: PEG ratios to find the optimized blend 
ratio for best antimicrobial results. 
 Study the release profile of SNP from the bioscaffolds by ICP-MS or ICP-OES. 
 Develop a methodology to determine the silver content of the nanocomposite 
scaffolds. 
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APPENDIX A:  EXPERIMENTAL PROTOCOLS 
A.1 HeLa Splitting and Seeding Procedure 
 
A.1.a Feeding 
A. Aspirate media  
B. Add 5ml new DMEM-RS+3%Fetal Bovine Serum per T-25 flask. (Note:  HeLa’s double 
every 24hrs- Will feed 1x/wk and split 1x/wk) 
C. Feed once a week for T-25 flask 
 
A.1.b Splitting Cells (volumes are per one T-25 of confluent HeLa’s) 
 
A. Aspirate media from flask to waste Stain 
B. Rinse w/ 5 ml CMF-PBS (Ca+ & Mg+ free) and swivel in flask 
C. Aspirate off PBS to waste 
D. Add 5 ml of Trypsin solution 
 
1) Wait ~10 minutes for cells to come off of the dish at room temperature.  Gently 
rock flask periodically and observe under microscope to make sure the cells are 
detaching. 
 
E. Add 5 ml of DMEM-RS+3%FBS to stop trypsin action 
F. Transfer suspension to a 50ml centrifuge tube. 
G. Spin down the cells at 1800rpm for 5 min on the centrifuge (Eppendorf 5702) 
H. Decant supernatant 
I. Resuspend in 5ml of DMEM-RS+3%FBS 
 
a) For Passaging: 
i. Add 5ml fresh DMEM-RS+3%FBS to a new T-25 flask 
ii. Add 3-5 drops of the cell suspension in the new T-25 flask for flask passaging. 
 
b) For Experiment: 
i. Perform cell count on 5mL of fresh DMEM+ suspended cells 
ii. Use Cell Seeding Calculator to determine the amount of cell suspension and 
additional fresh DMEM to add to achieve desired cell seeding density/dish 
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A.2. Flow-Based Methods 
A.2.a. Flow Cytometry: SYTOX Green Fluorescent Validation Protocol for Controls 
A. Observe and take brightfield images of cells seeded in 12-well plate before harvesting 
a. Negative control well is left as it is. 
b. Induce apoptosis for positive control (2 mM H2O2) for 4 hrs 
 
B. For Negative and Positive control: 
a) Aspirate the 0.6 ml DMEM RS (+3% FBS) cell solution from 12 well plate 
b) Wash with 0.6 ml PBS (with Calcium and Magnesium) 
c) Collect the DMEM and PBS solution containing the floaters in 15 ml tubes 
d) Add 0.6 mL 0.25% trypsin.  Allow 5-7 minutes for cells to detach from the 
bottom of the dish. 
e) Add 0.6 mL of DMEM-RS (+3% FBS) 
f) Add trypsin and DMEM solution to 15 ml tube containing the floaters 
g) Spin down at 18000 rpm on mini-spin for 5 minutes 
h) Aspirate carefully using 1 mL pipettor 
i) Re-suspend pallet in 1 ml PBS 
j) Add 5 ul of 5 uM Sytox Green stain (Molecular Probes) (Staining steps are done 
under the hood with the light off) 
k) Allow 15 minutes for cells to stain with Sytox 
l) Spin down at 18000 rpm on mini-spin for 5 minutes 
m) Aspirate carefully using 1 mL pipettor 
n) Re-suspend pallet in 250 ul 1% PFA  
o) Transfer cells in solution to 5 mL cytometer tube 
 
C. Run flow cytometry at Veterinary Medicine 
a. Take labeled sheet and numbered tubes to Vet Med with cell sample tubes 
covered in foil and on ice 
b. Analyze samples on flow cytometer using appropriate filter settings 
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A.2.b. Flow Cytometry: SYTOX Green Fluorescent Validation Protocol for Coatings 
A. Harvest cells 
1) Add 1 ml 2.6x106 cell/ml cell solution for 24 hrs. 
2) Aspirate the 1 ml DMEM RS (+3% FBS) cell solution from pertri dishes 
3) Wash with 1 ml PBS (with Calcium and Magnesium) 
4) Collect the DMEM and PBS solution containing the floaters in 15 ml tubes 
 
B. Trypsinization  
1) Add 1 mL 0.25% trypsin.  Allow 5-7 minutes for cells to detach from the bottom 
of the dish. 
2) Add 1 mL of DMEM-RS (+3% FBS) 
3) Collect trypsin and DMEM solution to 15 ml tube containing the floaters 
 
C. Centrifuge 
1) Spin down 4 ml cell solution at 18000 rpm on mini-spin for 5minutes 
2) Aspirate carefully using 1 mL pipettor 
3) Re-suspend pallet in 1 ml PBS 
 
D. Stain  (Staining steps are done under the hood with the light off) 
1) Add 5 ul of 5 uM Sytox Green stain (Molecular Probes) (Staining steps are done 
under the hood with the light off) 
2) Allow 15 minutes for cells to stain with Sytox 
 
E. Centrifuge 
1) Spin down PBS/Sytox Green solution at 18000 rpm on mini-spin for 5minutes 
 
F. Fix cells 
1) Re-suspend pallet in 250 ul 1% PFA 
2) Transfer cells in solution to 5 mL cytometer tube 
 
F. Run flow cytometry at Veterinary Medicine 
a. Take labeled sheet and numbered tubes to Vet Med with cell sample tubes 
covered in foil and on ice 
b. Analyze samples on flow cytometer using appropriate filter settings 
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APPENDIX B:  TGA RESULTS 
B.1 TGA Results to Quantify SNP Amount 
 
 
 
 The percent SNP present in the coatings is calculated based on the TGA values 
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Graph processed to show the percent SNP left after the TGA experiment 
 
 
Table shows the initial and final measured amount of SNP after TGA experiment on 
different coating with varying concentrations of SNP (700 ppm-5000 ppm). The percent SNP 
added in the PLLA coatings and the expected weight is based on the required concentration of 
SNP. The final SNP weight is obtained from TGA and the values are lower than the detection 
limit of the instrument. 
    
Initial  
  
Final 
  
Samples 
Added 
SNP(%) 
Weight 
Sample(mg) 
Expected SNP 
weight Weight SNP 
Percent 
SNP 
No SNP 0 2.025 0 0.02168655 1.071153914 
600 ppm 0.06 4.363 0.0026178 0.03590965 0.823018 
700 ppm 0.07 4.202 0.0029414 0.03246498 0.772682 
1000 
ppm 0.1 3.253 0.003253 0.02413368 0.742027 
1500 
ppm 0.15 2.663 0.0039945 0.01847267 0.693554 
2000 
ppm 0.2 2.699 0.005398 0.02399444 0.889137 
5000 
ppm 0.5 2.351 0.011755 0.02852249 1.213272 
 
 92 
B.2 TGA Results to Quantify the Release Profile of SNP 
 
 
 
The percent SNP present in the coatings is calculated based on the TGA values 
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Graph processed to show the percent SNP left after the TGA experiment  
 
 
Table shows the initial and final measured amount of SNP after TGA experiment on 700 
ppm coating over a period of 6 days. The percent SNP added in the PLLA coatings and the 
expected weight is based on the required concentration of SNP. The final SNP weight is obtained 
from TGA and the values are lower than the detection limit of the instrument. 
 
  
Initial 
 
Final 
 
Samples 
Added 
SNP(%) 
Weight 
Sample(mg) Initial SNP weight 
Weight SNP 
(mg) Percent SNP 
No SNP 0 2.025 0 0.02168655 1.071153914 
700 ppm 
(D1) 0.07 4.202 0.0029414 0.03246498 0.772682 
700 ppm 
(D2) <0.07 15.139  0.20504 1.354444 
700 ppm 
(D5) <0.07 20.388  0.2460537 1.206996 
700 ppm 
(D6) <0.07 11.754  0.1436768 1.222509 
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